{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:24:51Z","timestamp":1794608691195,"version":"4.9.1"},"reference-count":259,"publisher":"Bentham Science Publishers Ltd.","issue":"13","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>The global burden of neurological disorders is evident, yet there remains limited efficacious\ntherapeutics for their treatment. There is a growing recognition of the role of inflammation\nin diseases of the central nervous system (CNS); among the numerous inflammatory mediators involved,\nprostaglandins play a crucial role. Prostaglandins are small lipid mediators derived from\narachidonic acid via multi-enzymatic pathways. The actions of prostaglandins are varied, with\neach prostaglandin having a specific role in maintaining homeostasis. In the CNS, prostaglandins\ncan have neuroprotective or neurotoxic properties depending on their specific G-protein receptor.\nThese G-protein receptors have varying subfamilies, tissue distribution, and signal transduction\ncascades. Further studies into the impact of prostaglandins in CNS-based diseases may contribute\nto the clarification of their actions, hopefully leading to the development of efficacious therapeutic\nstrategies. This review focuses on the roles played by prostaglandins in neural degeneration, with\na focus on Alzheimer\u2019s Disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis in both\npreclinical and clinical settings. We further discuss current prostaglandin-related agonists and antagonists\nconcerning suggestions for their use as future therapeutics.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0113894501323980240815113851","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:57:30Z","timestamp":1724414250000},"page":"885-908","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Prostaglandins in the Inflamed Central Nervous System: Potential Therapeutic Targets"],"prefix":"10.2174","volume":"25","author":[{"given":"Chynna-Loren","family":"Sheremeta","sequence":"first","affiliation":[{"name":"Institute for Molecular Biosciences, The University of\nQueensland, St. Lucia, QLD 4072, Australia"},{"name":"School of Biomedical Sciences, The University of\nQueensland, St. Lucia, QLD 4072, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Yarlagadda","sequence":"additional","affiliation":[{"name":"Institute for Molecular Biosciences, The University of\nQueensland, St. Lucia, QLD 4072, Australia"},{"name":"School of Biomedical Sciences, The University of\nQueensland, St. Lucia, QLD 4072, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark L.","family":"Smythe","sequence":"additional","affiliation":[{"name":"Institute for Molecular Biosciences, The University of\nQueensland, St. Lucia, QLD 4072, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9821-8478","authenticated-orcid":true,"given":"Peter G.","family":"Noakes","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences, The University of\nQueensland, St. Lucia, QLD 4072, Australia"},{"name":"Queensland Brain Institute, The University of\nQueensland, St. Lucia, QLD 4072, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.pharmthera.2004.06.003","volume":"103","author":"Hata A.N.","year":"2004","unstructured":"Hata A.N.; Breyer R.M.; Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation. Pharmacol Ther  2004,103(2),147-166","journal-title":"Pharmacol Ther"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","volume":"31","author":"Ricciotti E.","year":"2011","unstructured":"Ricciotti E.; FitzGerald G.A.; Prostaglandins and Inflammation. Arterioscler Thromb Vasc Biol  2011,31(5),986-1000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2018.08.001","volume":"193","author":"Peebles R.S.","year":"2019","unstructured":"Peebles R.S.; Prostaglandins in asthma and allergic diseases. Pharmacol Ther  2019,193,1-19","journal-title":"Pharmacol Ther"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3390\/cells8060619","volume":"8","author":"Rittchen S.","year":"2019","unstructured":"Rittchen S.; Heinemann A.; Therapeutic potential of hematopoietic prostaglandin D(2) synthase in allergic inflammation. Cells  2019,8(6),619","journal-title":"Cells"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.2174\/1871527320666210512013648","volume":"21","author":"Kursun O.","year":"2022","unstructured":"Kursun O.; Karatas H.; Bariskaner H.; Ozturk S.; Arachidonic acid metabolites in neurologic disorders. CNS Neurol Disord Drug Targets  2022,21(2),150-159","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/glia.20658","volume":"56","author":"de Oliveira A.C.P.","year":"2008","unstructured":"de Oliveira A.C.P.; Candelario-Jalil E.; Bhatia H.S.; Lieb K.; H\u00fcll M.; Fiebich B.L.; Regulation of prostaglandin E  synthase expression in activated primary rat microglia: Evidence for uncoupled regulation of mPGES-1 and COX-2. Glia  2008,56(8),844-855","journal-title":"Glia"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.neuro.2011.02.004","volume":"32","author":"Milatovic D.","year":"2011","unstructured":"Milatovic D.; Montine T.J.; Aschner M.; Prostanoid signaling: Dual role for prostaglandin E2 in neurotoxicity. Neurotoxicology  2011,32(3),312-319","journal-title":"Neurotoxicology"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1074\/jbc.M110.157362","volume":"286","author":"Brenneis C.","year":"2011","unstructured":"Brenneis C.; Coste O.; Altenrath K.; Angioni C.; Schmidt H.; Schuh C.D.; Zhang D.D.; Henke M.; Weigert A.; Br\u00fcne B.; Rubin B.; Nusing R.; Scholich K.; Geisslinger G.; Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation. J Biol Chem  2011,286(3),2331-2342","journal-title":"J Biol Chem"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12974-016-0780-7","volume":"14","author":"Bonfill-Teixidor E.","year":"2017","unstructured":"Bonfill-Teixidor E.; Otxoa-de-Amezaga A.; Font-Nieves M.; Sans-Fons M.G.; Planas A.M.; Differential expression of E-type prostanoid receptors 2 and 4 in microglia stimulated with lipopolysaccharide. J Neuroinflammation  2017,14(1),3","journal-title":"J Neuroinflammation"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1021\/jm401431x","volume":"57","author":"Ganesh T.","year":"2014","unstructured":"Ganesh T.; Prostanoid receptor EP2 as a therapeutic target. J Med Chem  2014,57(11),4454-4465","journal-title":"J Med Chem"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s11064-016-2168-6","volume":"42","author":"Xu J.","year":"2017","unstructured":"Xu J.; Xu Z.; Yan A.; Prostaglandin E2 EP4 receptor activation attenuates neuroinflammation and early brain injury induced by subarachnoid hemorrhage in rats. Neurochem Res  2017,42(4),1267-1278","journal-title":"Neurochem Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"7207","DOI":"10.4049\/jimmunol.0903487","volume":"184","author":"Shi J.","year":"2010","unstructured":"Shi J.; Johansson J.; Woodling N.S.; Wang Q.; Montine T.J.; Andreasson K.; The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J Immunol  2010,184(12),7207-7218","journal-title":"J Immunol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.pharmthera.2013.03.006","volume":"138","author":"Konya V.","year":"2013","unstructured":"Konya V.; Marsche G.; Schuligoi R.; Heinemann A.; E-type prostanoid receptor 4 (EP4) in disease and therapy. Pharmacol Ther  2013,138(3),485-502","journal-title":"Pharmacol Ther"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/FJC.0b013e3182244a12","volume":"59","author":"Tang E.H.C.","year":"2012","unstructured":"Tang E.H.C.; Libby P.; Vanhoutte P.M.; Xu A.; Anti-inflammation therapy by activation of prostaglandin EP4 receptor in cardiovascular and other inflammatory diseases. J Cardiovasc Pharmacol  2012,59(2),116-123","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.4049\/jimmunol.1300290","volume":"192","author":"Morimoto K.","year":"2014","unstructured":"Morimoto K.; Shirata N.; Taketomi Y.; Tsuchiya S.; Segi-Nishida E.; Inazumi T.; Kabashima K.; Tanaka S.; Murakami M.; Narumiya S.; Sugimoto Y.; Prostaglandin E2-EP3 signaling induces inflammatory swelling by mast cell activation. J Immunol  2014,192(3),1130-1137","journal-title":"J Immunol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1398-9995.2006.01043.x","volume":"61","author":"Wang X.S.","year":"2006","unstructured":"Wang X.S.; Lau H.Y.A.; Prostaglandin E  potentiates the immunologically stimulated histamine release from human peripheral blood-derived mast cells through EP1\/EP3 receptors. Allergy  2006,61(4),503-506","journal-title":"Allergy"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.prostaglandins.2009.04.003","volume":"91","author":"Andreasson K.","year":"2010","unstructured":"Andreasson K.; Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat  2010,91(3-4),104-112","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.bbalip.2014.07.008","volume":"1851","author":"Kawahara K.","year":"2015","unstructured":"Kawahara K.; Hohjoh H.; Inazumi T.; Tsuchiya S.; Sugimoto Y.; Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors. Biochim Biophys Acta Mol Cell Biol Lipids  2015,1851(4),414-421","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"6254","DOI":"10.3390\/ijms20246254","volume":"20","author":"Mizuno R.","year":"2019","unstructured":"Mizuno R.; Kawada K.; Sakai Y.; Prostaglandin E2\/EP signaling in the tumor microenvironment of colorectal cancer. Int J Mol Sci  2019,20(24),6254","journal-title":"Int J Mol Sci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/503128","volume":"2012","author":"Joo M.","year":"2012","unstructured":"Joo M.; Sadikot R.T.; PGD synthase and PGD2 in immune resposne. Mediators Inflamm  2012,2012,1-6","journal-title":"Mediators Inflamm"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.4049\/jimmunol.143.9.2982","volume":"143","author":"Urade Y.","year":"1989","unstructured":"Urade Y.; Ujihara M.; Horiguchi Y.; Ikai K.; Hayaishi O.; The major source of endogenous prostaglandin D2 production is likely antigen-presenting cells. Localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues. J Immunol  1989,143(9),2982-2989","journal-title":"J Immunol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1111\/all.14161","volume":"75","author":"Xia J.","year":"2020","unstructured":"Xia J.; Abdu S.; Maguire T.J.A.; Hopkins C.; Till S.J.; Woszczek G.; Prostaglandin D  receptors in human mast cells. Allergy  2020,75(6),1477-1480","journal-title":"Allergy"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.4049\/jimmunol.164.5.2277","volume":"164","author":"Tanaka K.","year":"2000","unstructured":"Tanaka K.; Ogawa K.; Sugamura K.; Nakamura M.; Takano S.; Nagata K.; Cutting edge: differential production of prostaglandin D2 by human helper T cell subsets. J Immunol  2000,164(5),2277-2280","journal-title":"J Immunol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"15277","DOI":"10.1074\/jbc.M506431200","volume":"281","author":"Aritake K.","year":"2006","unstructured":"Aritake K.; Kado Y.; Inoue T.; Miyano M.; Urade Y.; Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase. J Biol Chem  2006,281(22),15277-15286","journal-title":"J Biol Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1046\/j.1471-4159.1995.65062690.x","volume":"65","author":"Minghetti L.","year":"1995","unstructured":"Minghetti L.; Levi G.; Induction of prostanoid biosynthesis by bacterial lipopolysaccharide and isoproterenol in rat microglial cultures. J Neurochem  1995,65(6),2690-2698","journal-title":"J Neurochem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1073\/pnas.96.2.726","volume":"96","author":"Eguchi N.","year":"1999","unstructured":"Eguchi N.; Minami T.; Shirafuji N.; Kanaoka Y.; Tanaka T.; Nagata A.; Yoshida N.; Urade Y.; Ito S.; Hayaishi O.; Lack of tactile pain (allodynia) in lipocalin-type prostaglandin D synthase-deficient mice. Proc Natl Acad Sci USA  1999,96(2),726-730","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12974-021-02361-2","volume":"18","author":"Iwasa K.","year":"2021","unstructured":"Iwasa K.; Yamamoto S.; Yamashina K.; Yagishita-kyo N.; Maruyama K.; Awaji T.; Takei Y.; Hirasawa A.; Yoshikawa K.; A peripheral lipid sensor GPR120 remotely contributes to suppression of PGD-microglia-provoked neuroinflammation and neurodegeneration in the mouse hippocampus. J Neuroinflammation  2021,18(1),304","journal-title":"J Neuroinflammation"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/0024-3205(82)90101-1","volume":"31","author":"Narumiya S.","year":"1982","unstructured":"Narumiya S.; Ogorochi T.; Nakao K.; Hayaishi O.; Prostaglandin D2 in rat brain, spinal cord and pituitary: Basal level and regional distribution. Life Sci  1982,31(19),2093-2103","journal-title":"Life Sci"},{"key":"ref=29","first-page":"429","volume":"6","author":"Hayaishi O.","year":"1993","unstructured":"Hayaishi O.; Matsumura H.; Urade Y.; Prostaglandin D synthase is the key enzyme in the promotion of physiological sleep. J Lipid Mediat  1993,6(1-3),429-431","journal-title":"J Lipid Mediat"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/sj.bjp.0702490","volume":"127","author":"Crider J.Y.","year":"1999","unstructured":"Crider J.Y.; Griffin B.W.; Sharif N.A.; Prostaglandin DP receptors positively coupled to adenylyl cyclase in embryonic bovine tracheal (EBTr) cells: pharmacological characterization using agonists and antagonists. Br J Pharmacol  1999,127(1),204-210","journal-title":"Br J Pharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1124\/jpet.103.050955","volume":"306","author":"Hata A.N.","year":"2003","unstructured":"Hata A.N.; Zent R.; Breyer M.D.; Breyer R.M.; Expression and molecular pharmacology of the mouse CRTH2 receptor. J Pharmacol Exp Ther  2003,306(2),463-470","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.4049\/jimmunol.177.4.2621","volume":"177","author":"Satoh T.","year":"2006","unstructured":"Satoh T.; Moroi R.; Aritake K.; Urade Y.; Kanai Y.; Sumi K.; Yokozeki H.; Hirai H.; Nagata K.; Hara T.; Utsuyama M.; Hirokawa K.; Sugamura K.; Nishioka K.; Nakamura M.; Prostaglandin D2 plays an essential role in chronic allergic inflammation of the skin via CRTH2 receptor. J Immunol  2006,177(4),2621-2629","journal-title":"J Immunol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.4049\/jimmunol.179.4.2565","volume":"179","author":"Joo M.","year":"2007","unstructured":"Joo M.; Kwon M.; Sadikot R.T.; Kingsley P.J.; Marnett L.J.; Blackwell T.S.; Peebles R.S.; Urade Y.; Christman J.W.; Induction and function of lipocalin prostaglandin D synthase in host immunity. J Immunol  2007,179(4),2565-2575","journal-title":"J Immunol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1523\/JNEUROSCI.4531-05.2006","volume":"26","author":"Mohri I.","year":"2006","unstructured":"Mohri I.; Taniike M.; Taniguchi H.; Kanekiyo T.; Aritake K.; Inui T.; Fukumoto N.; Eguchi N.; Kushi A.; Sasai H.; Kanaoka Y.; Ozono K.; Narumiya S.; Suzuki K.; Urade Y.; Prostaglandin D2-mediated microglia\/astrocyte interaction enhances astrogliosis and demyelination in twitcher. J Neurosci  2006,26(16),4383-4393","journal-title":"J Neurosci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0952-3278(03)00080-2","volume":"69","author":"Kabashima K.","year":"2003","unstructured":"Kabashima K.; Narumiya S.; The DP receptor, allergic inflammation and asthma. Prostaglandins Leukot Essent Fatty Acids  2003,69(2-3),187-194","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"24646","DOI":"10.1038\/srep24646","volume":"6","author":"Ma J.","year":"2016","unstructured":"Ma J.; Yang Q.; Wei Y.; Yang Y.; Ji C.; Hu X.; Mai S.; Kuang S.; Tian X.; Luo Y.; Liang G.; Yang J.; Effect of the PGD2-DP signaling pathway on primary cultured rat hippocampal neuron injury caused by aluminum overload. Sci Rep  2016,6(1),24646","journal-title":"Sci Rep"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.imlet.2005.10.004","volume":"102","author":"Herlong J.L.","year":"2006","unstructured":"Herlong J.L.; Scott T.R.; Positioning prostanoids of the D and J series in the immunopathogenic scheme. Immunol Lett  2006,102(2),121-131","journal-title":"Immunol Lett"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/sj.bjp.0704973","volume":"137","author":"Sawyer N.","year":"2002","unstructured":"Sawyer N.; Cauchon E.; Chateauneuf A.; Cruz R.P.G.; Nicholson D.W.; Metters K.M.; O\u2019Neill G.P.; Gervais F.G.; Molecular pharmacology of the human prostaglandin D  receptor, CRTH2. Br J Pharmacol  2002,137(8),1163-1172","journal-title":"Br J Pharmacol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejphar.2015.11.004","volume":"785","author":"Marion-Letellier R.","year":"2016","unstructured":"Marion-Letellier R.; Savoye G.; Ghosh S.; Fatty acids, eicosanoids and PPAR gamma. Eur J Pharmacol  2016,785,44-49","journal-title":"Eur J Pharmacol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ejmech.2019.01.067","volume":"166","author":"Mirza A.Z.","year":"2019","unstructured":"Mirza A.Z.; Althagafi I.I.; Shamshad H.; Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications. Eur J Med Chem  2019,166,502-513","journal-title":"Eur J Med Chem"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fphar.2011.00024","volume":"2","author":"Stitham J.","year":"2011","unstructured":"Stitham J.; Midgett C.; Martin K.A.; Hwa J.; Prostacyclin: an inflammatory paradox. Front Pharmacol  2011,2,24","journal-title":"Front Pharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1A","DOI":"10.1016\/j.amjcard.2012.12.002","volume":"111","author":"Waxman A.B.","year":"2013","unstructured":"Waxman A.B.; Zamanian R.T.; Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies. Am J Cardiol  2013,111(5),1A-16A","journal-title":"Am J Cardiol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.rmed.2010.12.018","volume":"105","author":"Safdar Z.","year":"2011","unstructured":"Safdar Z.; Treatment of pulmonary arterial hypertension: The role of prostacyclin and prostaglandin analogs. Respir Med  2011,105(6),818-827","journal-title":"Respir Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/bph.14167","volume":"176","author":"Mitchell J.A.","year":"2019","unstructured":"Mitchell J.A.; Kirkby N.S.; Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. Br J Pharmacol  2019,176(8),1038-1050","journal-title":"Br J Pharmacol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1046\/j.1460-9568.1999.00791.x","volume":"11","author":"Satoh T.","year":"1999","unstructured":"Satoh T.; Ishikawa Y.; Kataoka Y.; Cui Y.; Yanase H.; Kato K.; Watanabe Y.; Nakadate K.; Matsumura K.; Hatanaka H.; Kataoka K.; Noyori R.; Suzuki M.; Watanabe Y.; CNS-specific prostacyclin ligands as neuronal survival-promoting factors in the brain. Eur J Neurosci  1999,11(9),3115-3124","journal-title":"Eur J Neurosci"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1016\/0006-2952(79)90055-8","volume":"28","author":"Gryglewski R.J.","year":"1979","unstructured":"Gryglewski R.J.; Prostacyclin as a circulatory hormone. Biochem Pharmacol  1979,28(21),3161-3166","journal-title":"Biochem Pharmacol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1212\/WNL.34.11.1431","volume":"34","author":"Miller V.T.","year":"1984","unstructured":"Miller V.T.; Coull B.M.; Yatsu F.M.; Shah A.B.; Beamer N.B.; Prostacyclin infusion in acute cerebral infarction. Neurology  1984,34(11),1431-1435","journal-title":"Neurology"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1074\/jbc.271.10.5901","volume":"271","author":"Takechi H.","year":"1996","unstructured":"Takechi H.; Matsumura K.; Watanabe Y.; Kato K.; Noyori R.; Suzuki M.; Watanabe Y.; A novel subtype of the prostacyclin receptor expressed in the central nervous system. J Biol Chem  1996,271(10),5901-5906","journal-title":"J Biol Chem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"e795","DOI":"10.1038\/cddis.2013.335","volume":"4","author":"Takahashi C.","year":"2013","unstructured":"Takahashi C.; Muramatsu R.; Fujimura H.; Mochizuki H.; Yamashita T.; Prostacyclin promotes oligodendrocyte precursor recruitment and remyelination after spinal cord demyelination. Cell Death Dis  2013,4(9),e795-e795","journal-title":"Cell Death Dis"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1744-9081-10-42","volume":"10","author":"Yu L.","year":"2014","unstructured":"Yu L.; Yang B.; Wang J.; Zhao L.; Luo W.; Jiang Q.; Yang J.; Time course change of COX2-PGI2\/TXA2 following global cerebral ischemia reperfusion injury in rat hippocampus. Behav Brain Funct  2014,10(1),42","journal-title":"Behav Brain Funct"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1097\/TA.0b013e3181a5f211","volume":"67","author":"Jungner M.","year":"2009","unstructured":"Jungner M.; Bentzer P.; Gr\u00e4nde P.O.; Prostacyclin reduces elevation of intracranial pressure and plasma volume loss in lipopolysaccharide-induced meningitis in the cat. J Trauma  2009,67(6),1345-1351","journal-title":"J Trauma"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"769347","DOI":"10.3389\/fncel.2022.769347","volume":"16","author":"Womack T.R.","year":"2022","unstructured":"Womack T.R.; Vollert C.T.; Ohia-Nwoko O.; Schmitt M.; Montazari S.; Beckett T.L.; Mayerich D.; Murphy M.P.; Eriksen J.L.; Prostacyclin promotes degenerative pathology in a model of Alzheimer\u2019s disease. Front Cell Neurosci  2022,16,769347","journal-title":"Front Cell Neurosci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/946813","volume":"2012","author":"Lima I.V.A.","year":"2012","unstructured":"Lima I.V.A.; Bastos L.F.S.; Limbor\u00e7o-Filho M.; Fiebich B.L.; de Oliveira A.C.P.; Role of prostaglandins in neuroinflammatory and neurodegenerative diseases. Mediators Inflamm  2012,2012,1-13","journal-title":"Mediators Inflamm"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10059-010-0157-1","volume":"30","author":"Basu S.","year":"2010","unstructured":"Basu S.; Bioactive eicosanoids: Role of prostaglandin F(2\u03b1) and F\u2082-isoprostanes in inflammation and oxidative stress related pathology. Mol Cells  2010,30(5),383-392","journal-title":"Mol Cells"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1016\/S0021-9258(17)41942-9","volume":"269","author":"Sakamoto K.","year":"1994","unstructured":"Sakamoto K.; Ezashi T.; Miwa K.; Okuda-Ashitaka E.; Houtani T.; Sugimoto T.; Ito S.; Hayaishi O.; Molecular cloning and expression of a cDNA of the bovine prostaglandin F2 \u03b1 receptor. J Biol Chem  1994,269(5),3881-3886","journal-title":"J Biol Chem"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/S0021-9258(17)42265-4","volume":"269","author":"Sugimoto Y.","year":"1994","unstructured":"Sugimoto Y.; Hasumoto K.; Namba T.; Irie A.; Katsuyama M.; Negishi M.; Kakizuka A.; Narumiya S.; Ichikawa A.; Cloning and expression of a cDNA for mouse prostaglandin F receptor. J Biol Chem  1994,269(2),1356-1360","journal-title":"J Biol Chem"},{"key":"ref=57","first-page":"424","volume":"42","author":"Mukhopadhyay P.","year":"2001","unstructured":"Mukhopadhyay P.; Bian L.; Yin H.; Bhattacherjee P.; Paterson C.; Localization of EP(1) and FP receptors in human ocular tissues by in situ hybridization. Invest Ophthalmol Vis Sci  2001,42(2),424-428","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1074\/jbc.271.2.1179","volume":"271","author":"Adams J.W.","year":"1996","unstructured":"Adams J.W.; Migita D.S.; Yu M.K.; Young R.; Hellickson M.S.; Castro-Vargas F.E.; Domingo J.D.; Lee P.H.; Bui J.S.; Henderson S.A.; Prostaglandin F2 \u03b1 stimulates hypertrophic growth of cultured neonatal rat ventricular myocytes. J Biol Chem  1996,271(2),1179-1186","journal-title":"J Biol Chem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/ane.12263","volume":"130","author":"\u0130nce H.","year":"2014","unstructured":"\u0130nce H.; Aydin \u00d6.F.; Ala\u00e7am H.; Aydin T.; Azak E.; \u00d6zy\u00fcrek H.; Urinary leukotriene E4 and prostaglandin F2a concentrations in children with migraine: A randomized study. Acta Neurol Scand  2014,130(3),188-192","journal-title":"Acta Neurol Scand"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/1742-2094-10-132","volume":"10","author":"Glushakov A.V.","year":"2013","unstructured":"Glushakov A.V.; Robbins S.W.; Bracy C.L.; Narumiya S.; Dor\u00e9 S.; Prostaglandin F2\u03b1 FP receptor antagonist improves outcomes after experimental traumatic brain injury. J Neuroinflammation  2013,10(1),132","journal-title":"J Neuroinflammation"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1136\/neurintsurg-2021-017504","volume":"14","author":"Wanderer S.","year":"2022","unstructured":"Wanderer S.; Andereggen L.; Mrosek J.; Kashefiolasl S.; Schubert G.A.; Marbacher S.; Konczalla J.; Levosimendan as a therapeutic strategy to prevent neuroinflammation after aneurysmal subarachnoid hemorrhage? J Neurointerv Surg  2022,14(4),408-412","journal-title":"J Neurointerv Surg"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1021\/acschemneuro.9b00333","volume":"10","author":"Walker K.A.","year":"2019","unstructured":"Walker K.A.; Ficek B.N.; Westbrook R.; Understanding the role of systemic inflammation in Alzheimer\u2019s disease. ACS Chem Neurosci  2019,10(8),3340-3342","journal-title":"ACS Chem Neurosci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/s41582-019-0240-y","volume":"15","author":"Matthews P.M.","year":"2019","unstructured":"Matthews P.M.; Chronic inflammation in multiple sclerosis \u2014 seeing what was always there. Nat Rev Neurol  2019,15(10),582-593","journal-title":"Nat Rev Neurol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"246","DOI":"10.2174\/156652411795243450","volume":"11","author":"McCombe P.A.","year":"2011","unstructured":"McCombe P.A.; Henderson R.D.; The role of immune and inflammatory mechanisms in ALS. Curr Mol Med  2011,11(3),246-254","journal-title":"Curr Mol Med"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.cell.2010.02.016","volume":"140","author":"Glass C.K.","year":"2010","unstructured":"Glass C.K.; Saijo K.; Winner B.; Marchetto M.C.; Gage F.H.; Mechanisms underlying inflammation in neurodegeneration. Cell  2010,140(6),918-934","journal-title":"Cell"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.3892\/mmr.2016.4948","volume":"13","author":"Chen W.W.","year":"2016","unstructured":"Chen W.W.; Zhang X.; Huang W.J.; Role of neuroinflammation in neurodegenerative diseases (Review). Mol Med Rep  2016,13(4),3391-3396","journal-title":"Mol Med Rep"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1007\/s12035-015-9355-3","volume":"53","author":"Yagami T.","year":"2016","unstructured":"Yagami T.; Koma H.; Yamamoto Y.; Pathophysiological roles of cyclooxygenases and prostaglandins in the central nervous system. Mol Neurobiol  2016,53(7),4754-4771","journal-title":"Mol Neurobiol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/DNND.S240800","volume":"10","author":"Famitafreshi H.","year":"2020","unstructured":"Famitafreshi H.; Karimian M.; Prostaglandins as the agents that modulate the course of brain disorders. Degener Neurol Neuromuscul Dis  2020,10,1-13","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"Hardy J.","year":"2002","unstructured":"Hardy J.; Selkoe D.J.; The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics. Science  2002,297(5580),353-356","journal-title":"Science"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12079-020-00585-0","volume":"15","author":"Biringer R.G.","year":"2021","unstructured":"Biringer R.G.; A Review of prostanoid receptors: Expression, characterization, regulation, and mechanism of action. J Cell Commun Signal  2021,15(2),155-184","journal-title":"J Cell Commun Signal"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/pro.2524","volume":"23","author":"Ow S.Y.","year":"2014","unstructured":"Ow S.Y.; Dunstan D.E.; A brief overview of amyloids and Alzheimer\u2019s disease. Protein Sci  2014,23(10),1315-1331","journal-title":"Protein Sci"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrn2967","volume":"12","author":"Ittner L.M.","year":"2011","unstructured":"Ittner L.M.; G\u00f6tz J.; Amyloid-\u03b2 and tau \u2014 A toxic pas de deux in Alzheimer\u2019s disease. Nat Rev Neurosci  2011,12(2),67-72","journal-title":"Nat Rev Neurosci"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12974-022-02567-y","volume":"19","author":"Dong Y.","year":"2022","unstructured":"Dong Y.; Yu H.; Li X.; Bian K.; Zheng Y.; Dai M.; Feng X.; Sun Y.; He Y.; Yu B.; Zhang H.; Wu J.; Yu X.; Wu H.; Kong W.; Hyperphosphorylated tau mediates neuronal death by inducing necroptosis and inflammation in Alzheimer\u2019s disease. J Neuroinflammation  2022,19(1),205","journal-title":"J Neuroinflammation"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fneur.2013.00009","volume":"4","author":"Kerrigan T.L.","year":"2013","unstructured":"Kerrigan T.L.; Randall A.D.; A new player in the \u201csynaptopathy\u201d of Alzheimer\u2019s disease - arc\/arg 3.1. Front Neurol  2013,4,9","journal-title":"Front Neurol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"937133","DOI":"10.3389\/fnmol.2022.937133","volume":"15","author":"Goel P.","year":"2022","unstructured":"Goel P.; Chakrabarti S.; Goel K.; Bhutani K.; Chopra T.; Bali S.; Neuronal cell death mechanisms in Alzheimer\u2019s disease: An insight. Front Mol Neurosci  2022,15,937133","journal-title":"Front Mol Neurosci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/WAD.0b013e3182163b62","volume":"26","author":"Apostolova L.G.","year":"2012","unstructured":"Apostolova L.G.; Green A.E.; Babakchanian S.; Hwang K.S.; Chou Y.Y.; Toga A.W.; Thompson P.M.; Hippocampal atrophy and ventricular enlargement in normal aging, mild cognitive impairment (MCI), and Alzheimer Disease. Alzheimer Dis Assoc Disord  2012,26(1),17-27","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1093\/brain\/awt273","volume":"136","author":"Andrade-Moraes C.H.","year":"2013","unstructured":"Andrade-Moraes C.H.; Oliveira-Pinto A.V.; Castro-Fonseca E.; da Silva C.G.; Guimar\u00e3es D.M.; Szczupak D.; Parente-Bruno D.R.; Carvalho L.R.B.; Polichiso L.; Gomes B.V.; Oliveira L.M.; Rodriguez R.D.; Leite R.E.P.; Ferretti-Rebustini R.E.L.; Jacob-Filho W.; Pasqualucci C.A.; Grinberg L.T.; Lent R.; Cell number changes in Alzheimer\u2019s disease relate to dementia, not to plaques and tangles. Brain  2013,136(12),3738-3752","journal-title":"Brain"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/2096595819896178","volume":"5","author":"Han F.","year":"2019","unstructured":"Han F.; Liu C.; Huang J.; Chen J.; Wei C.; Geng X.; Liu Y.; Han D.; Li M.; The application of patient-derived induced pluripotent stem cells for modeling and treatment of Alzheimer\u2019s disease. Brain Sci Advan  2019,5(1),21-40","journal-title":"Brain Sci Advan"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13195-018-0459-7","volume":"11","author":"Parnetti L.","year":"2019","unstructured":"Parnetti L.; Chipi E.; Salvadori N.; D\u2019Andrea K.; Eusebi P.; Prevalence and risk of progression of preclinical Alzheimer\u2019s disease stages: A systematic review and meta-analysis. Alzheimers Res Ther  2019,11(1),7","journal-title":"Alzheimers Res Ther"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3233\/JAD-161149","volume":"57","author":"Robinson M.","year":"2017","unstructured":"Robinson M.; Lee B.Y.; Hane F.T.; Recent progress in Alzheimer\u2019s disease research, part 2: Genetics and epidemiology. J Alzheimers Dis  2017,57(2),317-330","journal-title":"J Alzheimers Dis"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/nrd3505","volume":"10","author":"Karran E.","year":"2011","unstructured":"Karran E.; Mercken M.; Strooper B.D.; The amyloid cascade hypothesis for Alzheimer\u2019s disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov  2011,10(9),698-712","journal-title":"Nat Rev Drug Discov"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X15666170116143743","volume":"15","author":"Ricciarelli R.","year":"2017","unstructured":"Ricciarelli R.; Fedele E.; The amyloid cascade hypothesis in Alzheimer\u2019s disease: It\u2019s time to change our mind. Curr Neuropharmacol  2017,15(6),926-935","journal-title":"Curr Neuropharmacol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"109070","DOI":"10.1016\/j.intimp.2022.109070","volume":"110","author":"Wang Z.","year":"2022","unstructured":"Wang Z.; Weaver D.F.; Microglia and microglial-based receptors in the pathogenesis and treatment of Alzheimer\u2019s disease. Int Immunopharmacol  2022,110,109070","journal-title":"Int Immunopharmacol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2174\/1568010054022051","volume":"4","author":"Tzeng S.F.","year":"2005","unstructured":"Tzeng S.F.; Hsiao H.Y.; Mak O.T.; Prostaglandins and cyclooxygenases in glial cells during brain inflammation. Curr Drug Targets Inflamm Allergy  2005,4(3),335-340","journal-title":"Curr Drug Targets Inflamm Allergy"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s10787-021-00889-6","volume":"29","author":"Dhapola R.","year":"2021","unstructured":"Dhapola R.; Hota S.S.; Sarma P.; Bhattacharyya A.; Medhi B.; Reddy D.H.; Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer\u2019s disease. Inflammopharmacology  2021,29(6),1669-1681","journal-title":"Inflammopharmacology"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.bbadis.2015.11.011","volume":"1862","author":"Janssen B.","year":"2016","unstructured":"Janssen B.; Vugts D.J.; Funke U.; Molenaar G.T.; Kruijer P.S.; van Berckel B.N.M.; Lammertsma A.A.; Windhorst A.D.; Imaging of neuroinflammation in Alzheimer\u2019s disease, multiple sclerosis and stroke: Recent developments in positron emission tomography. Biochim Biophys Acta Mol Basis Dis  2016,1862(3),425-441","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1742-2094-11-120","volume":"11","author":"Zimmer E.R.","year":"2014","unstructured":"Zimmer E.R.; Leuzy A.; Benedet A.L.; Breitner J.; Gauthier S.; Rosa-Neto P.; Tracking neuroinflammation in Alzheimer\u2019s disease: The role of positron emission tomography imaging. J Neuroinflammation  2014,11(1),120","journal-title":"J Neuroinflammation"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.neurobiolaging.2012.09.012","volume":"34","author":"Sudduth T.L.","year":"2013","unstructured":"Sudduth T.L.; Schmitt F.A.; Nelson P.T.; Wilcock D.M.; Neuroinflammatory phenotype in early Alzheimer\u2019s disease. Neurobiol Aging  2013,34(4),1051-1059","journal-title":"Neurobiol Aging"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13195-015-0126-1","volume":"7","author":"Gomez-Nicola D.","year":"2015","unstructured":"Gomez-Nicola D.; Boche D.; Post-mortem analysis of neuroinflammatory changes in human Alzheimer\u2019s disease. Alzheimers Res Ther  2015,7(1),42","journal-title":"Alzheimers Res Ther"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt24","volume":"2","author":"Zotova E.","year":"2010","unstructured":"Zotova E.; Nicoll J.A.R.; Kalaria R.; Holmes C.; Boche D.; Inflammation in Alzheimer\u2019s disease: Relevance to pathogenesis and therapy. Alzheimers Res Ther  2010,2(1),1","journal-title":"Alzheimers Res Ther"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","volume":"4","author":"Kinney J.W.","year":"2018","unstructured":"Kinney J.W.; Bemiller S.M.; Murtishaw A.S.; Leisgang A.M.; Salazar A.M.; Lamb B.T.; Inflammation as a central mechanism in Alzheimer\u2019s disease. Alzheimers Dement (N Y)  2018,4(1),575-590","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13195-016-0207-9","volume":"8","author":"Cummings J.","year":"2016","unstructured":"Cummings J.; Aisen P.S.; DuBois B.; Fr\u00f6lich L.; Jack C.R.; Jones R.W.; Morris J.C.; Raskin J.; Dowsett S.A.; Scheltens P.; Drug development in Alzheimer\u2019s disease: The path to 2025. Alzheimers Res Ther  2016,8(1),39","journal-title":"Alzheimers Res Ther"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1097\/00005072-199911000-00003","volume":"58","author":"Yermakova A.V.","year":"1999","unstructured":"Yermakova A.V.; Rollins J.; Callahan L.M.; Rogers J.; O\u02bcBanion M.K.; Cyclooxygenase-1 in human Alzheimer and control brain: Quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol  1999,58(11),1135-1146","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1159\/000101957","volume":"23","author":"Fujimi K.","year":"2007","unstructured":"Fujimi K.; Noda K.; Sasaki K.; Wakisaka Y.; Tanizaki Y.; Iida M.; Kiyohara Y.; Kanba S.; Iwaki T.; Altered expression of COX-2 in subdivisions of the hippocampus during aging and in Alzheimer\u2019s disease: The Hisayama Study. Dement Geriatr Cogn Disord  2007,23(6),423-431","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"53S","DOI":"10.2967\/jnumed.121.263199","volume":"63","author":"Kenou B.V.","year":"2022","unstructured":"Kenou B.V.; Manly L.S.; Rubovits S.B.; Umeozulu S.A.; Van Buskirk M.G.; Zhang A.S.; Pike V.W.; Zanotti-Fregonara P.; Henter I.D.; Innis R.B.; Cyclooxygenases as potential PET imaging biomarkers to explore neuroinflammation in dementia. J Nucl Med  2022,63,53S-59S","journal-title":"J Nucl Med"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/1568007054038201","volume":"4","author":"Hoozemans J.","year":"2005","unstructured":"Hoozemans J.; O\u2019Banion M.; The role of COX-1 and COX-2 in Alzheimer\u2019s disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs. Curr Drug Targets CNS Neurol Disord  2005,4(3),307-315","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1096\/fj.201800355RRRR","volume":"33","author":"Guan P.P.","year":"2019","unstructured":"Guan P.P.; Wang P.; Integrated communications between cyclooxygenase-2 and Alzheimer\u2019s disease. FASEB J  2019,33(1),13-33","journal-title":"FASEB J"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neulet.2017.04.056","volume":"651","author":"Liu N.","year":"2017","unstructured":"Liu N.; Zhuang Y.; Zhou Z.; Zhao J.; Chen Q.; Zheng J.; NF-\u03baB dependent up-regulation of TRPC6 by A\u03b2 in BV-2 microglia cells increases COX-2 expression and contributes to hippocampus neuron damage. Neurosci Lett  2017,651,1-8","journal-title":"Neurosci Lett"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s004010000251","volume":"101","author":"Hoozemans J.J.M.","year":"2001","unstructured":"Hoozemans J.J.M.; Rozemuller A.J.M.; Janssen I.; De Groot C.J.A.; Veerhuis R.; Eikelenboom P.; Cyclooxygenase expression in microglia and neurons in Alzheimer\u2019s disease and control brain. Acta Neuropathol  2001,101(1),2-8","journal-title":"Acta Neuropathol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s43440-023-00481-5","volume":"75","author":"Montero-Cosme T.G.","year":"2023","unstructured":"Montero-Cosme T.G.; Pascual-Mathey L.I.; Hern\u00e1ndez-Aguilar M.E.; Herrera-Covarrubias D.; Rojas-Dur\u00e1n F.; Aranda-Abreu G.E.; Potential drugs for the treatment of Alzheimer\u2019s disease. Pharmacol Rep  2023,75(3),544-559","journal-title":"Pharmacol Rep"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3390\/ph15070827","volume":"15","author":"El-Malah A.A.","year":"2022","unstructured":"El-Malah A.A.; Gineinah M.M.; Deb P.K.; Khayyat A.N.; Bansal M.; Venugopala K.N.; Aljahdali A.S.; Selective COX-2 inhibitors: Road from success to controversy and the quest for repurposing. Pharmaceuticals (Basel)  2022,15(7),827","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"101729","DOI":"10.1016\/j.jsps.2023.101729","volume":"31","author":"Moussa N.","year":"2023","unstructured":"Moussa N.; Dayoub N.; Exploring the role of COX-2 in Alzheimer\u2019s disease: Potential therapeutic implications of COX-2 inhibitors. Saudi Pharm J  2023,31(9),101729","journal-title":"Saudi Pharm J"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/bmj.327.7407.128","volume":"327","author":"Etminan M.","year":"2003","unstructured":"Etminan M.; Gill S.; Samii A.; Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer\u2019s disease: Systematic review and meta-analysis of observational studies. BMJ  2003,327(7407),128","journal-title":"BMJ"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1212\/01.wnl.0000313813.48505.86","volume":"70","author":"Arvanitakis Z.","year":"2008","unstructured":"Arvanitakis Z.; Grodstein F.; Bienias J.L.; Schneider J.A.; Wilson R.S.; Kelly J.F.; Evans D.A.; Bennett D.A.; Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology  2008,70(23),2219-2225","journal-title":"Neurology"},{"key":"ref=105","first-page":"CD011459","volume":"4","author":"Jordan F.","year":"2020","unstructured":"Jordan F.; Quinn T.J.; McGuinness B.; Passmore P.; Kelly J.P.; Tudur Smith C.; Murphy K.; Devane D.; Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. Cochrane Database Syst Rev  2020,4(4),CD011459","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"CD006378","DOI":"10.1002\/14651858.CD006378.pub2","author":"Jaturapatporn D.","year":"2012","unstructured":"Jaturapatporn D.; Isaac M.G.E.K.N.; McCleery J.; Tabet N.; Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer\u2019s disease. Cochrane Libr  2012(2),CD006378","journal-title":"Cochrane Libr"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fnagi.2010.00019","volume":"2","author":"Imbimbo B.P.","year":"2010","unstructured":"Imbimbo B.P.; Solfrizzi V.; Panza F.; Are NSAIDs useful to treat Alzheimer\u2019s disease or mild cognitive impairment? Front Aging Neurosci  2010,2,19","journal-title":"Front Aging Neurosci"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3233\/JAD-170706","volume":"62","author":"McGeer P.L.","year":"2018","unstructured":"McGeer P.L.; Guo J.P.; Lee M.; Kennedy K.; McGeer E.G.; Alzheimer\u2019s disease can be spared by nonsteroidal anti-inflammatory drugs. J Alzheimers Dis  2018,62(3),1219-1222","journal-title":"J Alzheimers Dis"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1371\/journal.pctr.0010041","volume":"1","author":"Breitner J.C.S.","year":"2006","unstructured":"Breitner J.C.S.; Martin B.K.; Meinert C.L.; The suspension of treatments in ADAPT: Concerns beyond the cardiovascular safety of celecoxib or naproxen. PLoS Clin Trials  2006,1(8),e41","journal-title":"PLoS Clin Trials"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.3390\/ijerph16142560","volume":"16","author":"Biringer R.G.","year":"2019","unstructured":"Biringer R.G.; The role of eicosanoids in Alzheimer\u2019s disease. Int J Environ Res Public Health  2019,16(14),2560","journal-title":"Int J Environ Res Public Health"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s10571-022-01216-5","volume":"43","author":"Do K.V.","year":"2023","unstructured":"Do K.V.; Hjorth E.; Wang Y.; Jun B.; Kautzmann M.A.I.; Ohshima M.; Eriksdotter M.; Schultzberg M.; Bazan N.G.; Cerebrospinal fluid profile of lipid mediators in Alzheimer\u2019s disease. Cell Mol Neurobiol  2023,43(2),797-811","journal-title":"Cell Mol Neurobiol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1007\/s12035-015-9544-0","volume":"53","author":"Zhu M.","year":"2016","unstructured":"Zhu M.; Wang X.; Hjorth E.; Colas R.A.; Schroeder L.; Granholm A.C.; Serhan C.N.; Schultzberg M.; Pro-resolving lipid mediators improve neuronal survival and increase A\u03b242 phagocytosis. Mol Neurobiol  2016,53(4),2733-2749","journal-title":"Mol Neurobiol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13195-022-01084-7","volume":"14","author":"Ebright B.","year":"2022","unstructured":"Ebright B.; Assante I.; Poblete R.A.; Wang S.; Duro M.V.; Bennett D.A.; Arvanitakis Z.; Louie S.G.; Yassine H.N.; Eicosanoid lipidome activation in post-mortem brain tissues of individuals with APOE4 and Alzheimer\u2019s dementia. Alzheimers Res Ther  2022,14(1),152","journal-title":"Alzheimers Res Ther"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/01.jnen.0000240472.43038.27","volume":"66","author":"Mohri I.","year":"2007","unstructured":"Mohri I.; Kadoyama K.; Kanekiyo T.; Sato Y.; Kagitani-Shimono K.; Saito Y.; Suzuki K.; Kudo T.; Takeda M.; Urade Y.; Murayama S.; Taniike M.; Hematopoietic prostaglandin D synthase and DP1 receptor are selectively upregulated in microglia and astrocytes within senile plaques from human patients and in a mouse model of Alzheimer disease. J Neuropathol Exp Neurol  2007,66(6),469-480","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1471-4159.2004.02870.x","volume":"92","author":"Liang X.","year":"2005","unstructured":"Liang X.; Wu L.; Hand T.; Andreasson K.; Prostaglandin D  mediates neuronal protection via the DP1 receptor. J Neurochem  2005,92(3),477-486","journal-title":"J Neurochem"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3344\/kjp.2021.34.1.27","volume":"34","author":"Li Y.","year":"2021","unstructured":"Li Y.; Kim W.M.; Kim S.H.; You H.E.; Kang D.H.; Lee H.G.; Choi J.I.; Yoon M.H.; Prostaglandin D  contributes to cisplatin-induced neuropathic pain in rats via DP2 receptor in the spinal cord. Korean J Pain  2021,34(1),27-34","journal-title":"Korean J Pain"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"6412","DOI":"10.1073\/pnas.0701585104","volume":"104","author":"Kanekiyo T.","year":"2007","unstructured":"Kanekiyo T.; Ban T.; Aritake K.; Huang Z.L.; Qu W.M.; Okazaki I.; Mohri I.; Murayama S.; Ozono K.; Taniike M.; Goto Y.; Urade Y.; Lipocalin-type prostaglandin D synthase\/\u03b2-trace is a major amyloid \u03b2-chaperone in human cerebrospinal fluid. Proc Natl Acad Sci USA  2007,104(15),6412-6417","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"12579","DOI":"10.1038\/s41598-019-48819-5","volume":"9","author":"Kannaian B.","year":"2019","unstructured":"Kannaian B.; Sharma B.; Phillips M.; Chowdhury A.; Manimekalai M.S.S.; Adav S.S.; Ng J.T.Y.; Kumar A.; Lim S.; Mu Y.; Sze S.K.; Gr\u00fcber G.; Pervushin K.; Abundant neuroprotective chaperone Lipocalin-type prostaglandin D synthase (L-PGDS) disassembles the Amyloid-\u03b2 fibrils. Sci Rep  2019,9(1),12579","journal-title":"Sci Rep"},{"key":"ref=119","first-page":"166","volume":"2","author":"Maesaka J.K.","year":"2013","unstructured":"Maesaka J.K.; Sodam B.; Palaia T.; Ragolia L.; Batuman V.; Miyawaki N.; Shastry S.; Youmans S.; El-Sabban M.; Prostaglandin D2 synthase: Apoptotic factor in alzheimer plasma, inducer of reactive oxygen species, inflammatory cytokines and dialysis dementia. J Nephropathol  2013,2(3),166-180","journal-title":"J Nephropathol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"349185","DOI":"10.1155\/2008\/349185","volume":"2008","author":"Xu J.","year":"2008","unstructured":"Xu J.; Barger S.W.; Drew P.D.; The PPAR-gamma agonist 15-deoxy-delta-prostaglandin J(2) attenuates microglial production of IL-12 family cytokines: potential relevance to Alzheimer\u2019s disease. PPAR Res  2008,2008(1),349185","journal-title":"PPAR Res"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S0165-5728(01)00267-3","volume":"115","author":"Drew P.D.","year":"2001","unstructured":"Drew P.D.; Chavis J.A.; The cyclopentone prostaglandin 15-deoxy-\u039412,14 prostaglandin J2 represses nitric oxide, TNF-\u03b1, and IL-12 production by microglial cells. J Neuroimmunol  2001,115(1-2),28-35","journal-title":"J Neuroimmunol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1136\/jnnp.2005.063131","volume":"77","author":"Combrinck M.","year":"2006","unstructured":"Combrinck M.; Williams J.; De Berardinis M.A.; Warden D.; Puopolo M.; Smith A.D.; Minghetti L.; Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry  2006,77(1),85-88","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/jnr.23217","volume":"91","author":"Akitake Y.","year":"2013","unstructured":"Akitake Y.; Nakatani Y.; Kamei D.; Hosokawa M.; Akatsu H.; Uematsu S.; Akira S.; Kudo I.; Hara S.; Takahashi M.; Microsomal prostaglandin E synthase-1 is induced in alzheimer\u2019s disease and its deletion mitigates alzheimer\u2019s disease-like pathology in a mouse model. J Neurosci Res  2013,91(7),909-919","journal-title":"J Neurosci Res"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jalz.2007.10.015","volume":"4","author":"Chaudhry U.A.","year":"2008","unstructured":"Chaudhry U.A.; Zhuang H.; Crain B.J.; Dor\u00e9 S.; Elevated microsomal prostaglandin-E synthase-1 in Alzheimer\u2019s disease. Alzheimers Dement  2008,4(1),6-13","journal-title":"Alzheimers Dement"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.expneurol.2009.07.027","volume":"223","author":"Chaudhry U.","year":"2010","unstructured":"Chaudhry U.; Zhuang H.; Dor\u00e9 S.; Microsomal prostaglandin E synthase-2: Cellular distribution and expression in Alzheimer\u2019s disease. Exp Neurol  2010,223(2),359-365","journal-title":"Exp Neurol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1177\/15353702231179926","volume":"248","author":"Sluter M.N.","year":"2023","unstructured":"Sluter M.N.; Li Q.; Yasmen N.; Chen Y.; Li L.; Hou R.; Yu Y.; Yang C.Y.; Meibohm B.; Jiang J.; The inducible prostaglandin E synthase (mPGES-1) in neuroinflammatory disorders. Exp Biol Med (Maywood)  2023,248(9),811-819","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1172\/JCI77487","volume":"125","author":"Johansson J.U.","year":"2015","unstructured":"Johansson J.U.; Woodling N.S.; Wang Q.; Panchal M.; Liang X.; Trueba-Saiz A.; Brown H.D.; Mhatre S.D.; Loui T.; Andreasson K.I.; Prostaglandin signaling suppresses beneficial microglial function in Alzheimer\u2019s disease models. J Clin Invest  2015,125(1),350-364","journal-title":"J Clin Invest"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"10180","DOI":"10.1523\/JNEUROSCI.3591-05.2005","volume":"25","author":"Liang X.","year":"2005","unstructured":"Liang X.; Wang Q.; Hand T.; Wu L.; Breyer R.M.; Montine T.J.; Andreasson K.; Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer\u2019s disease. J Neurosci  2005,25(44),10180-10187","journal-title":"J Neurosci"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.1038\/s41467-023-41283-w","volume":"14","author":"Xia Y.","year":"2023","unstructured":"Xia Y.; Xiao Y.; Wang Z.H.; Liu X.; Alam A.M.; Haran J.P.; McCormick B.A.; Shu X.; Wang X.; Ye K.; Bacteroides Fragilis in the gut microbiomes of Alzheimer\u2019s disease activates microglia and triggers pathogenesis in neuronal C\/EBP\u03b2 transgenic mice. Nat Commun  2023,14(1),5471","journal-title":"Nat Commun"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.2174\/092986708785132915","volume":"15","author":"Cimino P.","year":"2008","unstructured":"Cimino P.; Keene C.; Breyer R.; Montine K.; Montine T.; Therapeutic targets in prostaglandin E2 signaling for neurologic disease. Curr Med Chem  2008,15(19),1863-1869","journal-title":"Curr Med Chem"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12264-010-0703-z","volume":"26","author":"Wei L.L.","year":"2010","unstructured":"Wei L.L.; Shen Y.D.; Zhang Y.C.; Hu X.Y.; Lu P.L.; Wang L.; Chen W.; Roles of the prostaglandin E2 receptors EP subtypes in Alzheimer\u2019s disease. Neurosci Bull  2010,26(1),77-84","journal-title":"Neurosci Bull"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1021\/acschemneuro.6b00016","volume":"7","author":"Woodling N.S.","year":"2016","unstructured":"Woodling N.S.; Andreasson K.I.; Untangling the web: Toxic and protective effects of neuroinflammation and PGE2 signaling in Alzheimer\u2019s disease. ACS Chem Neurosci  2016,7(4),454-463","journal-title":"ACS Chem Neurosci"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/j.neurobiolaging.2011.09.017","volume":"33","author":"Zhen G.","year":"2012","unstructured":"Zhen G.; Kim Y.T.; Li R.; Yocum J.; Kapoor N.; Langer J.; Dobrowolski P.; Maruyama T.; Narumiya S.; Dor\u00e9 S.; PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer\u2019s disease. Neurobiol Aging  2012,33(9),2215-2219","journal-title":"Neurobiol Aging"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/ana.23677","volume":"72","author":"Shi J.","year":"2012","unstructured":"Shi J.; Wang Q.; Johansson J.U.; Liang X.; Woodling N.S.; Priyam P.; Loui T.M.; Merchant M.; Breyer R.M.; Montine T.J.; Andreasson K.; Inflammatory prostaglandin E  signaling in a mouse model of Alzheimer disease. Ann Neurol  2012,72(5),788-798","journal-title":"Ann Neurol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/j.1471-4159.2011.07567.x","volume":"120","author":"Hoshino T.","year":"2012","unstructured":"Hoshino T.; Namba T.; Takehara M.; Murao N.; Matsushima T.; Sugimoto Y.; Narumiya S.; Suzuki T.; Mizushima T.; Improvement of cognitive function in Alzheimer\u2019s disease model mice by genetic and pharmacological inhibition of the EP  receptor. J Neurochem  2012,120(5),795-805","journal-title":"J Neurochem"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"5882","DOI":"10.1523\/JNEUROSCI.0410-14.2014","volume":"34","author":"Woodling N.S.","year":"2014","unstructured":"Woodling N.S.; Wang Q.; Priyam P.G.; Larkin P.; Shi J.; Johansson J.U.; Zagol-Ikapitte I.; Boutaud O.; Andreasson K.I.; Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling. J Neurosci  2014,34(17),5882-5894","journal-title":"J Neurosci"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/pcn.12092","volume":"68","author":"Fattahi M.J.","year":"2014","unstructured":"Fattahi M.J.; Mirshafiey A.; Positive and negative effects of prostaglandins in Alzheimer\u2019s disease. Psychiatry Clin Neurosci  2014,68(1),50-60","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.prostaglandins.2013.09.002","volume":"106","author":"Zhuang J.","year":"2013","unstructured":"Zhuang J.; Zhang H.; Zhou R.; Chen L.; Chen J.; Shen X.; Regulation of prostaglandin F2\u03b1 against \u03b2 amyloid clearance and its inflammation induction through LXR\/RXR heterodimer antagonism in microglia. Prostaglandins Other Lipid Mediat  2013,106,45-52","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.brainresbull.2004.04.016","volume":"64","author":"Kim K.M.","year":"2004","unstructured":"Kim K.M.; Jung B.H.; Paeng K.J.; Kim I.; Chung B.C.; Increased urinary F2-isoprostanes levels in the patients with Alzheimer\u2019s disease. Brain Res Bull  2004,64(1),47-51","journal-title":"Brain Res Bull"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/alz.12081","volume":"16","author":"Trares K.","year":"2020","unstructured":"Trares K.; G\u00e0o X.; Perna L.; Rujescu D.; Stocker H.; M\u00f6llers T.; Beyreuther K.; Brenner H.; Sch\u00f6ttker B.; Associations of urinary 8-iso-prostaglandin F  levels with all-cause dementia, Alzheimer\u2019s disease, and vascular dementia incidence: results from a prospective cohort study. Alzheimers Dement  2020,16(5),804-813","journal-title":"Alzheimers Dement"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"101552","DOI":"10.1016\/j.arr.2021.101552","volume":"74","author":"Trares K.","year":"2022","unstructured":"Trares K.; Chen L.J.; Sch\u00f6ttker B.; Association of F-isoprostane levels with Alzheimer\u2019s disease in observational studies: A systematic review and meta-analysis. Ageing Res Rev  2022,74,101552","journal-title":"Ageing Res Rev"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1096\/fasebj.2020.34.s1.05459","volume":"34","author":"Womack T.","year":"2020","unstructured":"Womack T.; Eriksen J.L.; Effects of prostacyclin signaling on Alzheimer\u2019s disease associated pathologies. FASEB J  2020,34(S1),1-1","journal-title":"FASEB J"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.neuroscience.2008.07.073","volume":"156","author":"Wei G.","year":"2008","unstructured":"Wei G.; Kibler K.K.; Koehler R.C.; Maruyama T.; Narumiya S.; Dor\u00e9 S.; Prostacyclin receptor deletion aggravates hippocampal neuronal loss after bilateral common carotid artery occlusion in mouse. Neuroscience  2008,156(4),1111-1117","journal-title":"Neuroscience"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s11481-019-09896-5","volume":"15","author":"Ling Q.L.","year":"2020","unstructured":"Ling Q.L.; Akasaka H.; Chen C.; Haile C.N.; Winoske K.; Ruan K.H.; The protective effects of up-regulating prostacyclin biosynthesis on neuron survival in hippocampus. J Neuroimmune Pharmacol  2020,15(2),292-308","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"173554","DOI":"10.1016\/j.ejphar.2020.173554","volume":"887","author":"Vaz M.","year":"2020","unstructured":"Vaz M.; Silvestre S.; Alzheimer\u2019s disease: Recent treatment strategies. Eur J Pharmacol  2020,887,173554","journal-title":"Eur J Pharmacol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12974-021-02297-7","volume":"18","author":"Banik A.","year":"2021","unstructured":"Banik A.; Amaradhi R.; Lee D.; Sau M.; Wang W.; Dingledine R.; Ganesh T.; Prostaglandin EP2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of Alzheimer\u2019s disease. J Neuroinflammation  2021,18(1),273","journal-title":"J Neuroinflammation"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"10019","DOI":"10.1073\/pnas.1818544116","volume":"116","author":"Liu Q.","year":"2019","unstructured":"Liu Q.; Liang X.; Wang Q.; Wilson E.N.; Lam R.; Wang J.; Kong W.; Tsai C.; Pan T.; Larkin P.B.; Shamloo M.; Andreasson K.I.; PGE  signaling via the neuronal EP2 receptor increases injury in a model of cerebral ischemia. Proc Natl Acad Sci USA  2019,116(20),10019-10024","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1021\/acs.jmedchem.9b01218","volume":"63","author":"Amaradhi R.","year":"2020","unstructured":"Amaradhi R.; Banik A.; Mohammed S.; Patro V.; Rojas A.; Wang W.; Motati D.R.; Dingledine R.; Ganesh T.; Potent, selective, water soluble, brain-permeable EP2 receptor antagonist for use in central nervous system disease models. J Med Chem  2020,63(3),1032-1050","journal-title":"J Med Chem"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"11816","DOI":"10.1021\/acs.jmedchem.1c00816","volume":"64","author":"Sluter M.N.","year":"2021","unstructured":"Sluter M.N.; Hou R.; Li L.; Yasmen N.; Yu Y.; Liu J.; Jiang J.; EP2 Antagonists (2011-2021): A decade\u2019s journey from discovery to therapeutics. J Med Chem  2021,64(16),11816-11836","journal-title":"J Med Chem"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"1297175","DOI":"10.3389\/fimmu.2023.1297175","volume":"14","author":"Schlicher L.","year":"2023","unstructured":"Schlicher L.; Green L.G.; Romagnani A.; Renner F.; Small molecule inhibitors for cancer immunotherapy and associated biomarkers \u2013 The current status. Front Immunol  2023,14,1297175","journal-title":"Front Immunol"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.2174\/1381612826666200224112534","volume":"26","author":"Morofuji Y.","year":"2020","unstructured":"Morofuji Y.; Nakagawa S.; Drug development for central nervous system diseases using in vitro blood-brain barrier models and drug repositioning. Curr Pharm Des  2020,26(13),1466-1485","journal-title":"Curr Pharm Des"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"e202201555","DOI":"10.26508\/lsa.202201555","volume":"5","author":"Wallace C.H.","year":"2022","unstructured":"Wallace C.H.; Oliveros G.; Serrano P.A.; Rockwell P.; Xie L.; Figueiredo-Pereira M.; Timapiprant, a prostaglandin D2 receptor antagonist, ameliorates pathology in a rat Alzheimer\u2019s model. Life Sci Alliance  2022,5(12),e202201555","journal-title":"Life Sci Alliance"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1093\/brain\/awh452","volume":"128","author":"Heneka M.T.","year":"2005","unstructured":"Heneka M.T.; Sastre M.; Dumitrescu-Ozimek L.; Hanke A.; Dewachter I.; Kuiperi C.; O\u2019Banion K.; Klockgether T.; Van Leuven F.; Landreth G.E.; Acute treatment with the PPAR\u03b3 agonist pioglitazone and ibuprofen reduces glial inflammation and A\u03b21\u201342 levels in APPV717I transgenic mice. Brain  2005,128(6),1442-1453","journal-title":"Brain"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3233\/JAD-190864","volume":"73","author":"Chamberlain S.","year":"2020","unstructured":"Chamberlain S.; Gabriel H.; Strittmatter W.; Didsbury J.; An exploratory phase IIa study of the PPAR delta\/gamma agonist T3D-959 assessing metabolic and cognitive function in subjects with mild to moderate Alzheimer\u2019s disease. J Alzheimers Dis  2020,73(3),1085-1103","journal-title":"J Alzheimers Dis"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.2147\/DDDT.S367229","volume":"16","author":"Alhowail A.","year":"2022","unstructured":"Alhowail A.; Alsikhan R.; Alsaud M.; Aldubayan M.; Rabbani S.I.; Protective effects of pioglitazone on cognitive impairment and the underlying mechanisms: A review of literature. Drug Des Devel Ther  2022,16,2919-2931","journal-title":"Drug Des Devel Ther"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s12035-012-8259-8","volume":"46","author":"Chen Y.C.","year":"2012","unstructured":"Chen Y.C.; Wu J.S.; Tsai H.D.; Huang C.Y.; Chen J.J.; Sun G.Y.; Lin T.N.; Peroxisome proliferator-activated receptor gamma (PPAR-\u03b3) and neurodegenerative disorders. Mol Neurobiol  2012,46(1),114-124","journal-title":"Mol Neurobiol"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.3390\/cells12081116","volume":"12","author":"Steinke I.","year":"2023","unstructured":"Steinke I.; Govindarajulu M.; Pinky P.D.; Bloemer J.; Yoo S.; Ward T.; Schaedig T.; Young T.; Wibowo F.S.; Suppiramaniam V.; Amin R.H.; Selective PPAR-delta\/PPAR-gamma activation improves cognition in a model of Alzheimer\u2019s disease. Cells  2023,12(8),1116","journal-title":"Cells"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"666958","DOI":"10.3389\/fnins.2021.666958","volume":"15","author":"Saunders A.M.","year":"2021","unstructured":"Saunders A.M.; Burns D.K.; Gottschalk W.K.; Reassessment of Pioglitazone for Alzheimer\u2019s Disease. Front Neurosci  2021,15,666958","journal-title":"Front Neurosci"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","volume":"26","author":"Dobson R.","year":"2019","unstructured":"Dobson R.; Giovannoni G.; Multiple sclerosis \u2013 A review. Eur J Neurol  2019,26(1),27-40","journal-title":"Eur J Neurol"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/ana.21800","volume":"66","author":"Henderson A.P.D.","year":"2009","unstructured":"Henderson A.P.D.; Barnett M.H.; Parratt J.D.E.; Prineas J.W.; Multiple sclerosis: Distribution of inflammatory cells in newly forming lesions. Ann Neurol  2009,66(6),739-753","journal-title":"Ann Neurol"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1474-4422(14)70305-9","volume":"14","author":"Hemmer B.","year":"2015","unstructured":"Hemmer B.; Kerschensteiner M.; Korn T.; Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol  2015,14(4),406-419","journal-title":"Lancet Neurol"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00281-019-00765-0","volume":"41","author":"Ruiz F.","year":"2019","unstructured":"Ruiz F.; Vigne S.; Pot C.; Resolution of inflammation during multiple sclerosis. Semin Immunopathol  2019,41(6),711-726","journal-title":"Semin Immunopathol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/00004836-200110000-00006","volume":"33","author":"Buchman A.L.","year":"2001","unstructured":"Buchman A.L.; Side effects of corticosteroid therapy. J Clin Gastroenterol  2001,33(4),289-294","journal-title":"J Clin Gastroenterol"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","volume":"74","author":"Baker D.","year":"2017","unstructured":"Baker D.; Herrod S.S.; Alvarez-Gonzalez C.; Giovannoni G.; Schmierer K.; Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of Alemtuzumab. JAMA Neurol  2017,74(8),961-969","journal-title":"JAMA Neurol"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1177\/1352458513502572","volume":"19","author":"Comi G.","year":"2013","unstructured":"Comi G.; Disease-modifying treatments for progressive multiple sclerosis. Mult Scler  2013,19(11),1428-1436","journal-title":"Mult Scler"},{"key":"ref=166","first-page":"527","volume":"140","author":"Correale J.","year":"2017","unstructured":"Correale J.; Gait\u00e1n M.I.; Ysrraelit M.C.; Fiol M.P.; Progressive multiple sclerosis: From pathogenic mechanisms to treatment. Brain  2017,140(3),527-546","journal-title":"Brain"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.mayocp.2013.11.002","volume":"89","author":"Wingerchuk D.M.","year":"2014","unstructured":"Wingerchuk D.M.; Carter J.L.; Multiple sclerosis: Current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc  2014,89(2),225-240","journal-title":"Mayo Clin Proc"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/ana.21640","volume":"65","author":"Weiner H.L.","year":"2009","unstructured":"Weiner H.L.; The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease? Ann Neurol  2009,65(3),239-248","journal-title":"Ann Neurol"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"545","DOI":"10.12998\/wjcc.v3.i7.545","volume":"3","author":"Gajofatto A.","year":"2015","unstructured":"Gajofatto A.; Benedetti M.D.; Treatment strategies for multiple sclerosis: When to start, when to change, when to stop? World J Clin Cases  2015,3(7),545-555","journal-title":"World J Clin Cases"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"Hauser S.L.","year":"2020","unstructured":"Hauser S.L.; Cree B.A.C.; Treatment of multiple sclerosis: A review. Am J Med  2020,133(12),1380-1390.e2","journal-title":"Am J Med"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2174\/1871527319666200825164123","volume":"21","author":"Hoxha M.","year":"2022","unstructured":"Hoxha M.; Spahiu E.; Prendi E.; Zappacosta B.; A systematic review on the role of arachidonic acid pathway in multiple sclerosis. CNS Neurol Disord Drug Targets  2022,21(2),160-187","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3109\/08923971003667627","volume":"32","author":"Mirshafiey A.","year":"2010","unstructured":"Mirshafiey A.; Jadidi-Niaragh F.; Prostaglandins in pathogenesis and treatment of multiple sclerosis. Immunopharmacol Immunotoxicol  2010,32(4),543-554","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"ref=173","doi-asserted-by":"publisher","DOI":"10.15586\/codon.multiplesclerosis.2017.","author":"Palumbo S.","year":"2017","unstructured":"Palumbo S.;  Multiple Sclerosis: Perspectives in Treatment and Pathogenesis  2017","journal-title":"Multiple Sclerosis: Perspectives in Treatment and Pathogenesis"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.plefa.2013.08.008","volume":"89","author":"Palumbo S.","year":"2013","unstructured":"Palumbo S.; Bosetti F.; Alterations of brain eicosanoid synthetic pathway in multiple sclerosis and in animal models of demyelination: Role of cyclooxygenase-2. Prostaglandins Leukot Essent Fatty Acids  2013,89(5),273-278","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12974-023-02981-w","volume":"21","author":"Broos J.Y.","year":"2024","unstructured":"Broos J.Y.; van der Burgt R.T.M.; Konings J.; Rijnsburger M.; Werz O.; de Vries H.E.; Giera M.; Kooij G.; Arachidonic acid-derived lipid mediators in multiple sclerosis pathogenesis: Fueling or dampening disease progression? J Neuroinflammation  2024,21(1),21","journal-title":"J Neuroinflammation"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/B978-0-444-52001-2.00008-X","volume":"122","author":"Robinson A.P.","year":"2014","unstructured":"Robinson A.P.; Harp C.T.; Noronha A.; Miller S.D.; The experimental autoimmune encephalomyelitis (EAE) model of MS. Handb Clin Neurol  2014,122,173-189","journal-title":"Handb Clin Neurol"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"13537","DOI":"10.3390\/ijms232113537","volume":"23","author":"Vantaggiato L.","year":"2022","unstructured":"Vantaggiato L.; Shaba E.; Carleo A.; Bezzini D.; Pannuzzo G.; Luddi A.; Piomboni P.; Bini L.; Bianchi L.; Neurodegenerative disorder risk in Krabbe disease carriers. Int J Mol Sci  2022,23(21),13537","journal-title":"Int J Mol Sci"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00259-020-04842-7","volume":"48","author":"Coda A.R.","year":"2021","unstructured":"Coda A.R.; Anzilotti S.; Boscia F.; Greco A.; Panico M.; Gargiulo S.; Gramanzini M.; Zannetti A.; Albanese S.; Pignataro G.; Annunziato L.; Salvatore M.; Brunetti A.; De Berardinis P.; Quarantelli M.; Palma G.; Pappat\u00e0 S.; in vivo imaging of CNS microglial activation\/macrophage infiltration with combined [F]DPA-714-PET and SPIO-MRI in a mouse model of relapsing remitting experimental autoimmune encephalomyelitis. Eur J Nucl Med Mol Imaging  2021,48(1),40-52","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/jnen\/60.11.1062","volume":"60","author":"Wu Y.P.","year":"2001","unstructured":"Wu Y.P.; McMahon E.J.; Matsuda J.; Suzuki K.; Matsushima G.K.; Suzuki K.; Expression of immune-related molecules is downregulated in twitcher mice following bone marrow transplantation. J Neuropathol Exp Neurol  2001,60(11),1062-1074","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1742-2094-2-10","volume":"2","author":"Kagitani-Shimono K.","year":"2005","unstructured":"Kagitani-Shimono K.; Mohri I.; Fujitani Y.; Suzuki K.; Ozono K.; Urade Y.; Taniike M.; Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model. J Neuroinflammation  2005,2(1),10","journal-title":"J Neuroinflammation"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"102508","DOI":"10.1016\/j.jaut.2020.102508","volume":"114","author":"Zheng J.","year":"2020","unstructured":"Zheng J.; Sariol A.; Meyerholz D.; Zhang Q.; Abrahante Llor\u00e9ns J.E.; Narumiya S.; Perlman S.; Prostaglandin D2 signaling in dendritic cells is critical for the development of EAE. J Autoimmun  2020,114,102508","journal-title":"J Autoimmun"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1523\/JNEUROSCI.22-12-04885.2002","volume":"22","author":"Taniike M.","year":"2002","unstructured":"Taniike M.; Mohri I.; Eguchi N.; Beuckmann C.T.; Suzuki K.; Urade Y.; Perineuronal oligodendrocytes protect against neuronal apoptosis through the production of lipocalin-type prostaglandin D synthase in a genetic demyelinating model. J Neurosci  2002,22(12),4885-4896","journal-title":"J Neurosci"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/j.1476-5381.2011.01302.x","volume":"164","author":"Constantinescu C.S.","year":"2011","unstructured":"Constantinescu C.S.; Farooqi N.; O\u2019Brien K.; Gran B.; Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol  2011,164(4),1079-1106","journal-title":"Br J Pharmacol"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.neuint.2012.12.007","volume":"62","author":"Takeuchi C.","year":"2013","unstructured":"Takeuchi C.; Matsumoto Y.; Kohyama K.; Uematsu S.; Akira S.; Yamagata K.; Takemiya T.; Microsomal prostaglandin E synthase-1 aggravates inflammation and demyelination in a mouse model of multiple sclerosis. Neurochem Int  2013,62(3),271-280","journal-title":"Neurochem Int"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"21807","DOI":"10.1073\/pnas.0906891106","volume":"106","author":"Kihara Y.","year":"2009","unstructured":"Kihara Y.; Matsushita T.; Kita Y.; Uematsu S.; Akira S.; Kira J.; Ishii S.; Shimizu T.; Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis. Proc Natl Acad Sci USA  2009,106(51),21807-21812","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"12233","DOI":"10.1073\/pnas.0915112107","volume":"107","author":"Esaki Y.","year":"2010","unstructured":"Esaki Y.; Li Y.; Sakata D.; Yao C.; Segi-Nishida E.; Matsuoka T.; Fukuda K.; Narumiya S.; Dual roles of PGE  -EP4 signaling in mouse experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA  2010,107(27),12233-12238","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/med.21306","volume":"34","author":"Singh Bahia M.","year":"2014","unstructured":"Singh Bahia M.; Kumar Katare Y.; Silakari O.; Vyas B.; Silakari P.; Inhibitors of microsomal prostaglandin E2 synthase-1 enzyme as emerging anti-inflammatory candidates. Med Res Rev  2014,34(4),825-855","journal-title":"Med Res Rev"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"106383","DOI":"10.1016\/j.prostaglandins.2019.106383","volume":"147","author":"Bergqvist F.","year":"2020","unstructured":"Bergqvist F.; Morgenstern R.; Jakobsson P.J.; A review on mPGES-1 inhibitors: From preclinical studies to clinical applications. Prostaglandins Other Lipid Mediat  2020,147,106383","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"385","DOI":"10.4155\/fmc-2021-0317","volume":"14","author":"LaBorde K.","year":"2022","unstructured":"LaBorde K.; Lu R.; Ruan K.H.; Latest progress in the development of cyclooxygenase-2 pathway inhibitors targeting microsomal prostaglandin E synthase-1. Future Med Chem  2022,14(6),385-388","journal-title":"Future Med Chem"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/sj.gene.6363832","volume":"3","author":"Natarajan C.","year":"2002","unstructured":"Natarajan C.; Bright J.J.; Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun  2002,3(2),59-70","journal-title":"Genes Immun"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jneuroim.2004.12.015","volume":"161","author":"Storer P.D.","year":"2005","unstructured":"Storer P.D.; Xu J.; Chavis J.; Drew P.D.; Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: Implications for multiple sclerosis. J Neuroimmunol  2005,161(1-2),113-122","journal-title":"J Neuroimmunol"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jneuroim.2016.05.021","volume":"304","author":"Raine C.S.","year":"2017","unstructured":"Raine C.S.; Multiple sclerosis: The resolving lesion revealed. J Neuroimmunol  2017,304,2-6","journal-title":"J Neuroimmunol"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11010-016-2770-6","volume":"420","author":"Morel A.","year":"2016","unstructured":"Morel A.; Miller E.; Bijak M.; Saluk J.; The increased level of COX-dependent arachidonic acid metabolism in blood platelets from secondary progressive multiple sclerosis patients. Mol Cell Biochem  2016,420(1-2),85-94","journal-title":"Mol Cell Biochem"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0165-5728(84)90002-X","volume":"6","author":"Bolton C.","year":"1984","unstructured":"Bolton C.; Turner A.M.; Turk J.L.; Prostaglandin levels in cerebrospinal fluid from multiple sclerosis patients in remission and relapse. J Neuroimmunol  1984,6(3),151-159","journal-title":"J Neuroimmunol"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1212\/WNL.41.2_Part_1.322","volume":"41","author":"Dore-Duffy P.","year":"1991","unstructured":"Dore-Duffy P.; Ho S.Y.; Donovan C.; Cerebrospinal fluid eicosanoid levels. Neurology  1991,41(2_part_1),322-324","journal-title":"Neurology"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00313153","volume":"222","author":"Egg D.","year":"1980","unstructured":"Egg D.; Herold M.; Rumpl E.; G\u00fcnther R.; Prostaglandin F2 \u03b1 levels in human cerebrospinal fluid in normal and pathological conditions. J Neurol  1980,222(4),239-248","journal-title":"J Neurol"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1212\/WNL.36.12.1587","volume":"36","author":"Dore-Duffy P.","year":"1986","unstructured":"Dore-Duffy P.; Donaldson J.O.; Koff T.; Longo M.; Perry W.; Prostaglandin release in multiple sclerosis. Neurology  1986,36(12),1587-1590","journal-title":"Neurology"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.3324\/haematol.2019.219519","volume":"105","author":"Kooij G.","year":"2020","unstructured":"Kooij G.; Troletti C.D.; Leuti A.; Norris P.C.; Riley I.; Albanese M.; Ruggieri S.; Libreros S.; van der Pol S.M.A.; van het Hof B.; Schell Y.; Guerrera G.; Buttari F.; Mercuri N.B.; Centonze D.; Gasperini C.; Battistini L.; de Vries H.E.; Serhan C.N.; Chiurchi\u00f9 V.; Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction. Haematologica  2020,105(8),2056-2070","journal-title":"Haematologica"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1365-2796.2008.02035.x","volume":"265","author":"Mattsson N.","year":"2009","unstructured":"Mattsson N.; Yaong M.; Rosengren L.; Blennow K.; M\u00e5nsson J.E.; Andersen O.; Zetterberg H.; Haghighi S.; Zho I.; Pratico D.; Elevated cerebrospinal fluid levels of prostaglandin E2 and 15 -(S)- hydroxyeicosatetraenoic acid in multiple sclerosis. J Intern Med  2009,265(4),459-464","journal-title":"J Intern Med"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"P5.210","DOI":"10.1212\/WNL.84.14_supplement.P5.210.","volume":"84","author":"Paz Soldan M.","year":"2015","unstructured":"Paz Soldan M.; Schmidt L.; Wood B.; Rose J.; Carlson N.; Prostaglandin F2\u03b1 receptor mediates oligodendrocyte precursor injury\/death: Potential role in multiple sclerosis. Neurology  2015,84,P5.210","journal-title":"Neurology"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"e256","DOI":"10.1212\/NXI.0000000000000256","volume":"3","author":"Lam M.A.","year":"2016","unstructured":"Lam M.A.; Maghzal G.J.; Khademi M.; Piehl F.; Ratzer R.; Romme Christensen J.; Sellebjerg F.T.; Olsson T.; Stocker R.; Absence of systemic oxidative stress and increased CSF prostaglandin F  in progressive MS. Neurol Neuroimmunol Neuroinflamm  2016,3(4),e256","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0009-8981(01)00573-3","volume":"310","author":"Reiber H.","year":"2001","unstructured":"Reiber H.; Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta  2001,310(2),173-186","journal-title":"Clin Chim Acta"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1365-2990.2005.00690.x","volume":"32","author":"Kagitani-Shimono K.","year":"2006","unstructured":"Kagitani-Shimono K.; Mohri I.; Oda H.; Ozono K.; Suzuki K.; Urade Y.; Taniike M.; Lipocalin-type prostaglandin D synthase (\u03b2-trace) is upregulated in the \u03b1B-crystallin- positive oligodendrocytes and astrocytes in the chronic multiple sclerosis. Neuropathol Appl Neurobiol  2006,32(1),64-73","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/j.1468-1331.2009.02696.x","volume":"16","author":"Comabella M.","year":"2009","unstructured":"Comabella M.; Pradillo J.M.; Fern\u00e1ndez M.; R\u00edo J.; Lizasoain I.; Juli\u00e0 E.; Moro M.A.; Sastre-Garriga J.; Montalban X.; Plasma levels of 15d-PGJ  are not altered in multiple sclerosis. Eur J Neurol  2009,16(11),1197-1201","journal-title":"Eur J Neurol"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12987-020-00205-4","volume":"17","author":"Bergman J.","year":"2020","unstructured":"Bergman J.; Svenningsson A.; Liv P.; Bergenheim T.; Burman J.; Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS. Fluids Barriers CNS  2020,17(1),49","journal-title":"Fluids Barriers CNS"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"e24895","DOI":"10.7759\/cureus.24895","volume":"14","author":"Talanki Manjunatha R.","year":"2022","unstructured":"Talanki Manjunatha R.; Habib S.; Sangaraju S.L.; Yepez D.; Grandes X.A.; Multiple sclerosis: Therapeutic strategies on the horizon. Cureus  2022,14(5),e24895","journal-title":"Cureus"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1742-2094-1-3","volume":"1","author":"Pershadsingh H.A.","year":"2004","unstructured":"Pershadsingh H.A.; Heneka M.T.; Saini R.; Amin N.M.; Broeske D.J.; Feinstein D.L.; Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J Neuroinflammation  2004,1(1),3","journal-title":"J Neuroinflammation"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.plefa.2014.08.004","volume":"91","author":"Iwasa K.","year":"2014","unstructured":"Iwasa K.; Yamamoto S.; Takahashi M.; Suzuki S.; Yagishita S.; Awaji T.; Maruyama K.; Yoshikawa K.; Prostaglandin F2\u03b1 FP receptor inhibitor reduces demyelination and motor dysfunction in a cuprizone-induced multiple sclerosis mouse model. Prostaglandins Leukot Essent Fatty Acids  2014,91(5),175-182","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"bio059845","DOI":"10.1242\/bio.059845","volume":"12","author":"Daviaud N.","year":"2023","unstructured":"Daviaud N.; Chen E.; Edwards T.; Sadiq S.A.; Cerebral organoids in primary progressive multiple sclerosis reveal stem cell and oligodendrocyte differentiation defect. Biol Open  2023,12(3),bio059845","journal-title":"Biol Open"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1111\/ene.14393","volume":"27","author":"Masrori P.","year":"2020","unstructured":"Masrori P.; Van Damme P.; Amyotrophic lateral sclerosis: A clinical review. Eur J Neurol  2020,27(10),1918-1929","journal-title":"Eur J Neurol"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.genm.2010.11.010","volume":"7","author":"McCombe P.A.","year":"2010","unstructured":"McCombe P.A.; Henderson R.D.; Effects of gender in amyotrophic lateral sclerosis. Gend Med  2010,7(6),557-570","journal-title":"Gend Med"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ana.21543","volume":"65","author":"Rothstein J.D.","year":"2009","unstructured":"Rothstein J.D.; Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol  2009,65(S1),S3-S9","journal-title":"Ann Neurol"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ana.21437","volume":"64","author":"Liang X.","year":"2008","unstructured":"Liang X.; Wang Q.; Shi J.; Lokteva L.; Breyer R.M.; Montine T.J.; Andreasson K.; The prostaglandin E  EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann Neurol  2008,64(3),304-314","journal-title":"Ann Neurol"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12974-018-1217-2","volume":"15","author":"Lee J.D.","year":"2018","unstructured":"Lee J.D.; Levin S.C.; Willis E.F.; Li R.; Woodruff T.M.; Noakes P.G.; Complement components are upregulated and correlate with disease progression in the TDP-43 mouse model of amyotrophic lateral sclerosis. J Neuroinflammation  2018,15(1),171","journal-title":"J Neuroinflammation"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/bph.13730","volume":"174","author":"Lee J.D.","year":"2017","unstructured":"Lee J.D.; Kumar V.; Fung J.N.T.; Ruitenberg M.J.; Noakes P.G.; Woodruff T.M.; Pharmacological inhibition of complement C5a-C5a  receptor signalling ameliorates disease pathology in the hSOD1  mouse model of amyotrophic lateral sclerosis. Br J Pharmacol  2017,174(8),689-699","journal-title":"Br J Pharmacol"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ncl.2015.07.009","volume":"33","author":"Oskarsson B.","year":"2015","unstructured":"Oskarsson B.; Horton D.K.; Mitsumoto H.; Potential environmental factors in amyotrophic lateral sclerosis. Neurol Clin  2015,33(4),877-888","journal-title":"Neurol Clin"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/362059a0","volume":"362","author":"Rosen D.R.","year":"1993","unstructured":"Rosen D.R.; Siddique T.; Patterson D.; Figlewicz D.A.; Sapp P.; Hentati A.; Donaldson D.; Goto J.; O\u2019Regan J.P.; Deng H.X.; Rahmani Z.; Krizus A.; McKenna-Yasek D.; Cayabyab A.; Gaston S.M.; Berger R.; Tanzi R.E.; Halperin J.J.; Herzfeldt B.; Van den Bergh R.; Hung W-Y.; Bird T.; Deng G.; Mulder D.W.; Smyth C.; Laing N.G.; Soriano E.; Pericak-Vance M.A.; Haines J.; Rouleau G.A.; Gusella J.S.; Horvitz H.R.; Brown R.H.; Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature  1993,362(6415),59-62","journal-title":"Nature"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"e1000193","DOI":"10.1371\/journal.pgen.1000193","volume":"4","author":"Rutherford N.J.","year":"2008","unstructured":"Rutherford N.J.; Zhang Y.J.; Baker M.; Gass J.M.; Finch N.A.; Xu Y.F.; Stewart H.; Kelley B.J.; Kuntz K.; Crook R.J.P.; Sreedharan J.; Vance C.; Sorenson E.; Lippa C.; Bigio E.H.; Geschwind D.H.; Knopman D.S.; Mitsumoto H.; Petersen R.C.; Cashman N.R.; Hutton M.; Shaw C.E.; Boylan K.B.; Boeve B.; Graff-Radford N.R.; Wszolek Z.K.; Caselli R.J.; Dickson D.W.; Mackenzie I.R.; Petrucelli L.; Rademakers R.; Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet  2008,4(9),e1000193","journal-title":"PLoS Genet"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1126\/science.8209258","volume":"264","author":"Gurney M.E.","year":"1994","unstructured":"Gurney M.E.; Pu H.; Chiu A.Y.; Dal Canto M.C.; Polchow C.Y.; Alexander D.D.; Caliendo J.; Hentati A.; Kwon Y.W.; Deng H.X.; Chen W.; Zhai P.; Sufit R.L.; Siddique T.; Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science  1994,264(5166),1772-1775","journal-title":"Science"},{"key":"ref=220","first-page":"348765","volume":"2011","author":"Van Den Bosch L.","year":"2011","unstructured":"Van Den Bosch L.; Genetic rodent models of amyotrophic lateral sclerosis. J Biomed Biotechnol  2011,2011,348765","journal-title":"J Biomed Biotechnol"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s00335-011-9339-1","volume":"22","author":"Joyce P.I.","year":"2011","unstructured":"Joyce P.I.; Fratta P.; Fisher E.M.C.; Acevedo-Arozena A.; SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: Recent advances in understanding disease toward the development of clinical treatments. Mamm Genome  2011,22(7-8),420-448","journal-title":"Mamm Genome"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1152\/jn.00587.2012","volume":"110","author":"Bellingham M.C.","year":"2013","unstructured":"Bellingham M.C.; Pre- and postsynaptic mechanisms underlying inhibition of hypoglossal motor neuron excitability by riluzole. J Neurophysiol  2013,110(5),1047-1061","journal-title":"J Neurophysiol"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"CD001447","DOI":"10.1002\/14651858.CD001447.pub3","volume":"2012","author":"Miller R.G.","year":"2012","unstructured":"Miller R.G.; Mitchell J.D.; Moore D.H.; Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND). Cochrane Libr  2012,2012(3),CD001447","journal-title":"Cochrane Libr"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1038\/s41593-021-00944-z","volume":"24","author":"Lee H.","year":"2021","unstructured":"Lee H.; Lee J.J.; Park N.Y.; Dubey S.K.; Kim T.; Ruan K.; Lim S.B.; Park S.H.; Ha S.; Kovlyagina I.; Kim K.; Kim S.; Oh Y.; Kim H.; Kang S.U.; Song M.R.; Lloyd T.E.; Maragakis N.J.; Hong Y.B.; Eoh H.; Lee G.; Multi-omic analysis of selectively vulnerable motor neuron subtypes implicates altered lipid metabolism in ALS. Nat Neurosci  2021,24(12),1673-1685","journal-title":"Nat Neurosci"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.expneurol.2003.12.009","volume":"187","author":"Consilvio C.","year":"2004","unstructured":"Consilvio C.; Vincent A.M.; Feldman E.L.; Neuroinflammation, COX-2, and ALS\u2014a dual role? Exp Neurol  2004,187(1),1-10","journal-title":"Exp Neurol"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/jnen\/63.9.901","volume":"63","author":"Minghetti L.","year":"2004","unstructured":"Minghetti L.; Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol  2004,63(9),901-910","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s41984-022-00150-4","volume":"37","author":"Hanna L.","year":"2022","unstructured":"Hanna L.; Poluyi E.; Ikwuegbuenyi C.; Morgan E.; Imaguezegie G.; Peripheral inflammation and neurodegeneration; A potential for therapeutic intervention in Alzheimer\u2019s disease (AD), Parkinson\u2019s disease (PD) and amyotrophic lateral sclerosis (ALS). Egypt j neurosurg  2022,37(1),15","journal-title":"Egypt j neurosurg"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1002\/med.21725","volume":"41","author":"Kukharsky M.S.","year":"2021","unstructured":"Kukharsky M.S.; Skvortsova V.I.; Bachurin S.O.; Buchman V.L.; In a search for efficient treatment for amyotrophic lateral sclerosis: Old drugs for new approaches. Med Res Rev  2021,41(5),2804-2822","journal-title":"Med Res Rev"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40035-022-00322-0","volume":"11","author":"Agrawal I.","year":"2022","unstructured":"Agrawal I.; Lim Y.S.; Ng S.Y.; Ling S.C.; Deciphering lipid dysregulation in ALS: From mechanisms to translational medicine. Transl Neurodegener  2022,11(1),48","journal-title":"Transl Neurodegener"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/1531-8249(20010201)49:2<176::AID-ANA37>3.0.CO;2-X","volume":"49","author":"Almer G.","year":"2001","unstructured":"Almer G.; Gu\u00e9gan C.; Teismann P.; Naini A.; Rosoklija G.; Hays A.P.; Chen C.; Przedborski S.; Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol  2001,49(2),176-185","journal-title":"Ann Neurol"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1212\/WNL.57.6.952","volume":"57","author":"Yasojima K.","year":"2001","unstructured":"Yasojima K.; Tourtellotte W.W.; McGeer E.G.; McGeer P.L.; Marked increase in cyclooxygenase-2 in ALS spinal cord. Neurology  2001,57(6),952-956","journal-title":"Neurology"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1096\/fj.02-0876fje","volume":"17","author":"Pompl P.N.","year":"2003","unstructured":"Pompl P.N.; Ho L.; Bianchi M.; McManus T.; Qin W.; Pasinetti G.M.; A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J  2003,17(6),725-727","journal-title":"FASEB J"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3389\/fnins.2020.00817","volume":"14","author":"Zou Y.H.","year":"2020","unstructured":"Zou Y.H.; Guan P.P.; Zhang S.Q.; Guo Y.S.; Wang P.; Rofecoxib attenuates the pathogenesis of amyotrophic lateral sclerosis by alleviating cyclooxygenase-2-mediated mechanisms. Front Neurosci  2020,14,817","journal-title":"Front Neurosci"},{"key":"ref=234","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1186\/ar1794","volume":"7","author":"Borer J.S.","year":"2005","unstructured":"Borer J.S.; Simon L.S.; Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. Arthritis Res Ther  2005,7(Suppl 4),S14-S22","journal-title":"Arthritis Res Ther"},{"key":"ref=235","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1590\/2175-8239-jbn-2018-0107","volume":"41","author":"Lucas G.N.C.","year":"2019","unstructured":"Lucas G.N.C.; Leit\u00e3o A.C.C.; Alencar R.L.; Xavier R.M.F.; Daher E.D.F.; Silva Junior G.B.; Pathophysiological aspects of nephropathy caused by non-steroidal anti-inflammatory drugs. J Bras Nefrol  2019,41(1),124-130","journal-title":"J Bras Nefrol"},{"key":"ref=236","doi-asserted-by":"publisher","first-page":"28823","DOI":"10.1074\/jbc.274.40.28823","volume":"274","author":"Petrova T.V.","year":"1999","unstructured":"Petrova T.V.; Akama K.T.; Van Eldik L.J.; Selective modulation of BV-2 microglial activation by prostaglandin E(2). Differential effects on endotoxin-stimulated cytokine induction. J Biol Chem  1999,274(40),28823-28827","journal-title":"J Biol Chem"},{"key":"ref=237","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0006-8993(01)02432-5","volume":"908","author":"Kim E.J.","year":"2001","unstructured":"Kim E.J.; Lee J.E.; Kwon K.J.; Lee S.H.; Moon C.H.; Baik E.J.; Differential roles of cyclooxygenase isoforms after kainic acid-induced prostaglandin E2 production and neurodegeneration in cortical and hippocampal cell cultures. Brain Res  2001,908(1),1-9","journal-title":"Brain Res"},{"key":"ref=238","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1212\/WNL.58.8.1277","volume":"58","author":"Almer G.","year":"2002","unstructured":"Almer G.; Teismann P.; Stevic Z.; Halaschek-Wiener J.; Deecke L.; Kostic V.; Przedborski S.; Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology  2002,58(8),1277-1279","journal-title":"Neurology"},{"key":"ref=239","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40035-023-00366-w","volume":"12","author":"Nango H.","year":"2023","unstructured":"Nango H.; Tsuruta K.; Miyagishi H.; Aono Y.; Saigusa T.; Kosuge Y.; Update on the pathological roles of prostaglandin E in neurodegeneration in amyotrophic lateral sclerosis. Transl Neurodegener  2023,12(1),32","journal-title":"Transl Neurodegener"},{"key":"ref=240","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1034\/j.1600-0404.2003.00102.x","volume":"108","author":"I\u0142\u017cecka J.","year":"2003","unstructured":"I\u0142\u017cecka J.; Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients. Acta Neurol Scand  2003,108(2),125-129","journal-title":"Acta Neurol Scand"},{"key":"ref=241","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.neuint.2017.06.013","volume":"119","author":"Kosuge Y.","year":"2018","unstructured":"Kosuge Y.; Miyagishi H.; Yoneoka Y.; Yoneda K.; Nango H.; Ishige K.; Ito Y.; Pathophysiological role of prostaglandin E2-induced up-regulation of the EP2 receptor in motor neuron-like NSC-34 cells and lumbar motor neurons in ALS model mice. Neurochem Int  2018,119,132-139","journal-title":"Neurochem Int"},{"key":"ref=242","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1254\/jphs.12274SC","volume":"121","author":"Miyagishi H.","year":"2013","unstructured":"Miyagishi H.; Kosuge Y.; Yoneoka Y.; Ozone M.; Endo M.; Osada N.; Ishige K.; Kusama-Eguchi K.; Ito Y.; Prostaglandin E2-induced cell death is mediated by activation of EP2 receptors in motor neuron-like NSC-34 cells. J Pharmacol Sci  2013,121(4),347-350","journal-title":"J Pharmacol Sci"},{"key":"ref=243","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1021\/acsptsci.1c00255","volume":"5","author":"Amaradhi R.","year":"2022","unstructured":"Amaradhi R.; Mohammed S.; Banik A.; Franklin R.; Dingledine R.; Ganesh T.; Second-generation prostaglandin receptor EP2 antagonist, TG8-260, with high potency, selectivity, oral bioavailability, and anti-inflammatory properties. ACS Pharmacol Transl Sci  2022,5(2),118-133","journal-title":"ACS Pharmacol Transl Sci"},{"key":"ref=244","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.neuropharm.2019.02.011","volume":"149","author":"Jiang J.","year":"2019","unstructured":"Jiang J.; Yu Y.; Kinjo E.R.; Du Y.; Nguyen H.P.; Dingledine R.; Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury. Neuropharmacology  2019,149,149-160","journal-title":"Neuropharmacology"},{"key":"ref=245","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41586-020-03160-0","volume":"590","author":"Minhas P.S.","year":"2021","unstructured":"Minhas P.S.; Latif-Hernandez A.; McReynolds M.R.; Durairaj A.S.; Wang Q.; Rubin A.; Joshi A.U.; He J.Q.; Gauba E.; Liu L.; Wang C.; Linde M.; Sugiura Y.; Moon P.K.; Majeti R.; Suematsu M.; Mochly-Rosen D.; Weissman I.L.; Longo F.M.; Rabinowitz J.D.; Andreasson K.I.; Restoring metabolism of myeloid cells reverses cognitive decline in ageing. Nature  2021,590(7844),122-128","journal-title":"Nature"},{"key":"ref=246","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.bbrc.2011.10.045","volume":"415","author":"Shinozawa T.","year":"2011","unstructured":"Shinozawa T.; Urade Y.; Maruyama T.; Watabe D.; Tetranor PGDM analyses for the amyotrophic lateral sclerosis: Positive and simple diagnosis and evaluation of drug effect. Biochem Biophys Res Commun  2011,415(4),539-544","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=247","doi-asserted-by":"publisher","first-page":"7367","DOI":"10.1073\/pnas.112212599","volume":"99","author":"Kondo M.","year":"2002","unstructured":"Kondo M.; Shibata T.; Kumagai T.; Osawa T.; Shibata N.; Kobayashi M.; Sasaki S.; Iwata M.; Noguchi N.; Uchida K.; 15-Deoxy-\u0394  -prostaglandin J  : The endogenous electrophile that induces neuronal apoptosis. Proc Natl Acad Sci USA  2002,99(11),7367-7372","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=248","first-page":"2","volume":"1","author":"Thonhoff J.R.","year":"2011","unstructured":"Thonhoff J.R.; Gao J.; Dunn T.J.; Ojeda L.; Wu P.; Mutant SOD1 microglia-generated nitroxidative stress promotes toxicity to human fetal neural stem cell-derived motor neurons through direct damage and noxious interactions with astrocytes. Am J Stem Cells  2011,1(1),2-21","journal-title":"Am J Stem Cells"},{"key":"ref=249","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.stem.2008.09.017","volume":"3","author":"Di Giorgio F.P.","year":"2008","unstructured":"Di Giorgio F.P.; Boulting G.L.; Bobrowicz S.; Eggan K.C.; Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell  2008,3(6),637-648","journal-title":"Cell Stem Cell"},{"key":"ref=250","doi-asserted-by":"publisher","first-page":"248ra104","DOI":"10.1126\/scitranslmed.3009351","volume":"6","author":"de Boer A. S.","year":"2014","unstructured":"de Boer A. S.; Genetic validation of a therapeutic target in a mouse model of ALS. Sci Transl Med  2014,6(248),248ra104","journal-title":"Sci Transl Med"},{"key":"ref=251","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1111\/all.13174","volume":"72","author":"Okubo K.","year":"2017","unstructured":"Okubo K.; Hashiguchi K.; Takeda T.; Baba K.; Kitagoh H.; Miho H.; Tomomatsu H.; Yamaguchi S.; Odani M.; Yamamotoya H.; A randomized controlled phase II clinical trial comparing ONO -4053, a novel DP 1 antagonist, with a leukotriene receptor antagonist pranlukast in patients with seasonal allergic rhinitis. Allergy  2017,72(10),1565-1575","journal-title":"Allergy"},{"key":"ref=252","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejphar.2015.08.003","volume":"765","author":"Takahashi G.","year":"2015","unstructured":"Takahashi G.; Asanuma F.; Suzuki N.; Hattori M.; Sakamoto S.; Kugimiya A.; Tomita Y.; Kuwajima G.; Abraham W.M.; Deguchi M.; Arimura A.; Shichijo M.; Effect of the potent and selective DP1 receptor antagonist, asapiprant (S-555739), in animal models of allergic rhinitis and allergic asthma. Eur J Pharmacol  2015,765,15-23","journal-title":"Eur J Pharmacol"},{"key":"ref=253","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3390\/life11090994","volume":"11","author":"Yarlagadda S.","year":"2021","unstructured":"Yarlagadda S.; Kulis C.; Noakes P.G.; Smythe M.L.; Hematopoietic prostaglandin D synthase inhibitor PK007 decreases muscle necrosis in DMD mdx model mice. Life (Basel)  2021,11(9),994","journal-title":"Life (Basel)"},{"key":"ref=254","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/bpa.12350","volume":"26","author":"Loeffler J.P.","year":"2016","unstructured":"Loeffler J.P.; Picchiarelli G.; Dupuis L.; Gonzalez De Aguilar J.L.; The role of skeletal muscle in amyotrophic lateral sclerosis. Brain Pathol  2016,26(2),227-236","journal-title":"Brain Pathol"},{"key":"ref=255","doi-asserted-by":"publisher","first-page":"5252","DOI":"10.1038\/s41598-019-41771-4","volume":"9","author":"Tada S.","year":"2019","unstructured":"Tada S.; Okuno T.; Shimizu M.; Sakai Y.; Sumi-Akamaru H.; Kinoshita M.; Yamashita K.; Sanda E.; Choong C.J.; Namba A.; Sasaki T.; Koda T.; Takata K.; Miyagawa S.; Sawa Y.; Nakatsuji Y.; Mochizuki H.; Single injection of sustained-release prostacyclin analog ONO-1301-MS ameliorates hypoxic toxicity in the murine model of amyotrophic lateral sclerosis. Sci Rep  2019,9(1),5252","journal-title":"Sci Rep"},{"key":"ref=256","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1183\/16000617.0067-2015","volume":"24","author":"Lang I.M.","year":"2015","unstructured":"Lang I.M.; Gaine S.P.; Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension. Eur Respir Rev  2015,24(138),630-641","journal-title":"Eur Respir Rev"},{"key":"ref=257","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2006.12.015","volume":"26","author":"Benatar M.","year":"2007","unstructured":"Benatar M.; Lost in translation: Treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis  2007,26(1),1-13","journal-title":"Neurobiol Dis"},{"key":"ref=258","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13024-023-00619-2","volume":"18","author":"Fisher E.M.C.","year":"2023","unstructured":"Fisher E.M.C.; Greensmith L.; Malaspina A.; Fratta P.; Hanna M.G.; Schiavo G.; Isaacs A.M.; Orrell R.W.; Cunningham T.J.; Arozena A.A.; Opinion: more mouse models and more translation needed for ALS. Mol Neurodegener  2023,18(1),30","journal-title":"Mol Neurodegener"},{"key":"ref=259","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40478-022-01360-5","volume":"10","author":"Ding Q.","year":"2022","unstructured":"Ding Q.; Kesavan K.; Lee K.M.; Wimberger E.; Robertson T.; Gill M.; Power D.; Chang J.; Fard A.T.; Mar J.C.; Henderson R.D.; Heggie S.; McCombe P.A.; Jeffree R.L.; Colditz M.J.; Hilliard M.A.; Ng D.C.H.; Steyn F.J.; Phillips W.D.; Wolvetang E.J.; Ngo S.T.; Noakes P.G.; Impaired signaling for neuromuscular synaptic maintenance is a feature of motor neuron disease. Acta Neuropathol Commun  2022,10(1),61","journal-title":"Acta Neuropathol Commun"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501323980240815113851","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/233312\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501323980240815113851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T06:23:52Z","timestamp":1730874232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/233312\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":259,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113894501323980240815113851","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-04-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}